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1 
INTRODUCTION 
 
Parkinson‘s disease (PD) is the most common neurodegenerative disease 
of unknown etiology and characterized by motor symptoms of tremor, rigidity, 
bradykinesia, and postural instability. Parkinson‘s disease is characterized by an 
abnormal basal ganglia activity. Non-motor comorbidities, such as cognitive 
impairments (the comorbidity of anxiety and depression in Parkinson‘s disease) 
are likely the result of an intricate interplay of multi-system degenerations and 
neurotransmitter deficiencies extending beyond the loss of dopaminergic nigral 
neurons [1].  
The crude prevalence rate of PD in European countries has been found to 
range from 65.6 per 100,000 to 12,500 per 100,000, and the incidence from 5 per 
100,000 to 346 per 100,000. In Asian countries, the crude prevalence rates seem 
to be lower and range from 15 per 100,000 to 328 per 100,000 [2]. 
Several studies report data on the epidemiology of PD. However, 
methodological differences between studies make direct comparison of 
prevalence estimates difficult. It is generally accepted that the prevalence of the 
disease range from 1 to 2 per 1000 in unselected populations and that the 
disease affects 1% of the population above 60 years. The annual incidence per 
100,000 inhabitants ranges from less than 10 to more than 20. Incidence studies 
may be affected by under-diagnosing of PD, especially among the most elderly[3].  
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Etiology of PD 
 Environmental Factors 
 Genetic Factors 
Environmental Factors 
The specific etiology of Parkinson‘s disease (PD) is not known. Epidemiologic 
studies indicate that a number of factors may increase the risk of developing PD. 
These include, 
o Exposure to well water 
o Pesticides 
o Herbicides 
o Industrial chemicals 
o Wood pulp mills 
o Farming 
o Living in a rural environment. 
A number of exogenous toxins have been associated with the development of 
parkinsonism, including trace metals, cyanide, lacquer thinner, organic solvents, 
carbon monoxide, and carbon disulfide. There has also been interest in the 
possible role of endogenous toxins such as tetrahydroisoquinolines and beta-
carbolines. However, no specific toxin has been found in the brain of PD patients, 
and in many instances the Parkinsonism seen in association with toxins is not 
that of typical Lewy body PD. 
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Genetic Factors 
There has been considerable interest in the potential role of genetic factors in the 
etiology of PD. Approximately 5–10% of PD patients have a familial form of 
parkinsonism with an autosomal-dominant pattern of inheritance. Large 
pedigrees have been identified where members in different generations suffer 
from PD. This suggests that genetic factors are important in young-onset patients 
but are not likely to play a major role in patients with sporadic PD.  
There has been an extensive search for a mutation in the mitochondrial genome, 
based on the finding of a defect in mitochondrial complex I in the substantia nigra 
pars compacta (SNpc) of PD patients. Complex-I is composed of 41 subunits, 7 
of which are encoded by mitochondrial DNA (mtDNA) [4].  
Pathogenesis of PD 
PD suggests two major hypotheses regarding the pathogenesis of the disease. 
One hypothesis posits that misfolding and aggregation of proteins are 
instrumental in the death of SNpc dopaminergic neurons, while the other 
proposes that the culprit is mitochondrial dysfunction and the consequent 
oxidative stress, including toxic oxidized DA species. The abnormal deposition of 
protein in brain tissue is a feature of several age-related neurodegenerative 
diseases, including PD. Although the composition and location (i.e., intra- or 
extracellular) of protein aggregates differ from disease to disease, this common 
feature suggests that protein deposition per se, or some related event, is toxic to 
neurons. Aggregated or soluble misfolded proteins could be neurotoxic through a 
variety of mechanisms. Protein aggregates could directly cause damage, 
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perhaps by deforming the cell or interfering with intracellular trafficking in  
neurons [5]. 
Mechanisms of Neurodegeneration 
 Oxidative stress in Parkinson disease 
 Altered mitochondrial function in PD 
 Altered proteolysis in PD—proteasomal and lysosomal 
 Inflammatory change 
 Excitotoxic mechanisms 
Oxidative stress in Parkinson disease: 
Oxidative stress remains a cornerstone of the concepts underlying the loss of 
dopaminergic neurons in PD.  
                             Fig. No.1: Oxidative Stress and Parkinson’s disease 
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Since the 1980s there has been an exponential growth in publications that 
implicate the formation of reactive oxygen species as a final step in neuronal 
death of whatever origin. Increased free radical generation is almost impossible 
to detect, the potential inducers of oxidative stress and markers of its effects 
make a substantial case for its occurrence. Enhanced lipid peroxidation 
(malondialdehyde, lipid hydroperoxides, 4-hydroxynonenal, and advanced 
glycation end products), protein oxidation (protein carbonyls), and DNA oxidation 
(8-hydroxyguanosine) in the SNpc in PD and, perhaps, more generally 
throughout the body, all point in the same direction. 
Altered mitochondrial function in PD: 
Mitochondrial involvement in cell death in PD has returned to center stage 
and provides part of a unifying concept of how neuronal loss occurs in both 
sporadic and inherited disease. The discovery of the neurotoxicity of MPTP 
through its metabolite MPP+ identified a role for the inhibition of complex I in 
pathogenesis that is shared by other substances toxic to dopaminergic neurons, 
including rotenone and annonacin.  
Fig.No.2: Mitochondrial alterations associated with PD 
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Complex-I is the main gateway for electrons to enter the respiratory chain. 
It consists of 14 central and up to 32 accessory subunits, which form an L-
shaped complex with a membrane arm and a peripheral arm protruding into the 
mitochondrial matrix. Complex-I catalyze the electron transfer from NADH 
(derived from the tri-carboxylic acid cycle) to ubiquinone involving a flavin 
mononucleotide (FMN) and seven iron–sulfur clusters. The mitochondria are an 
important source of reactive oxygen species (ROS). Increased formation of 
mitochondrial ROS and/or defective ROS removal by mitochondrial defence 
systems results in oxidative damage to mtDNA, proteins and lipids and perturbs 
redox signaling pathways.  
The cause and the consequences of complex I deficiency in PD are not 
well understood. It has been suggested that mutations in complex I genes in the 
mitochondrial or nuclear genome can account for a dysfunction in complex I 
activity, assembly and/or stability. Many studies on complex I inhibition and ROS 
formation have been performed with rotenone, an inhibitor of complex I that binds 
in proximity to the quinone binding site. When pyruvate or glutamate plus malate 
are used as substrates to generate NADH and induce forward electron transport, 
rotenone blocks proton pumping and increases superoxide generation.  
Altered proteolysis in PD—proteasomal and lysosomal: 
The presence of multiple proteins in Lewy bodies, most notably ɑ-
synuclein, led to the idea that the catabolism of unwanted, damaged, or mutated 
proteins might be disrupted in PD, leading to cellular aggregation and neuronal 
death. This led to investigation of the roles of the ubiquitin–proteasome system 
(UPS) and lysosomes in pathogenesis in PD. Examination of the 26S 
proteasomein PD revealed selective changes in its catalytic activity and 
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composition in the SNc that were associated, perhaps wrongly, with impaired 
degradation of ɑ-synuclein [6]. 
Fig.No.3: The ubiquitin–proteasome system: genes involved in PD pathogenesis 
 
During proteolytic stress, here defined as a state in which the levels of 
unwanted proteins exceed the capacity for clearance due to increased protein 
production and/or inadequate proteolysis, undegraded proteins readily aggregate 
and become refractory to normal proteasomal activities. 
In some cases of familial PD, mutations in the genes encoding ɑ-
synuclein, parkin and ubiquitin C-terminal hydrolase L1, are associated with 
protein accumulation and Lewy body formation in the SNc, locus ceruleus and 
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cerebral cortex. In sporadic PD, the levels of oxidatively damaged proteins and 
protein aggregation are elevated in the SNc and in other brain regions.  
Further, ɑ-synuclein is a major component of Lewy bodies and, because of its 
normal predominance in presynaptic nerve terminals, this suggests retrograde 
transport as a means of accumulation to form inclusions. Consistent with this 
hypothesis, a recent study has shown that ɑ-synuclein is transported along with 
other proteins to form aggresomes in cell lines.  
Inflammatory change: 
The concept of inflammatory change in the brain in PD started with the 
description of activated HLA-positive microglia in SNc. Subsequently, alterations 
in the cytokines interleukin-1ɑ (IL-1ɑ), IL-1β, and tumor necrosis factor-ɑ (TNF-ɑ) 
were found in the brain and cerebrospinal fluid, and postmortem studies showed 
inducible nitric oxide (NO) synthase to be present in activated microglia.  
Fig.No.4: Relationship between peripheral inflammation and neuronal loss in PD 
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Inducible NO synthase is a source of NO, which in turn can react with 
superoxide from glial or neuronal sources to form the highly reactive peroxy-
nitrite. This can nitrate proteins and other biomolecules, and 3- nitro-tyrosine 
adducts are found in the SNpc in PD.  
Microglia activation and inflammatory change were thought to be a 
consequence of neuronal destruction but there is evidence for a more general 
systemic inflammatory reaction in PD, suggesting it to be a primary cause of 
neuronal loss in some cases. In addition, peripheral inflammation may enhance 
the adverse effects of inflammatory change occurring in the substantia nigra.                
Excitotoxic mechanisms: 
Excitotoxicity is always included in the list of pathogenic mechanisms that 
are thought to contribute to cell death in PD. However, the degree of direct 
evidence for this is small. The major contributor is the over activity of the sub-
thalamic nucleus (STN), which releases glutamate and which innervates the 
substantia nigra pars compacta and the internal segment of the globus pallidus.  
In addition, there is evidence of altered glutamatergic input from the 
corticostriatal pathway. Excitotoxicity might also arise from the dysfunction of 
mitochondria that occurs in PD. However, experimental studies show that 
excitotoxins can cause destruction of nigral dopaminergic neurons and that this 
process can be blocked by various classes of glutamate antagonists.  
The scenario would be that as PD develops with the onset of neuronal 
loss in the SNpc, the increased activity of the glutamatergic input from the STN 
acts to amplify cell death. Over activity of the glutamatergic output pathways from 
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the STN to the globus pallidus also contributes to the evolution of some of the 
clinical symptoms of PD.  
Indeed, deep brain stimulation (DBS) can correct the over activity of the 
STN, producing a clinical benefit in PD. Perhaps importantly, recent 
investigations utilizing DBS in PD have associated it with a lack of progression of 
motor symptoms [6]. 
ANIMAL MODELS OF PD 
Starting in the late nineteenth century, neuroscientists began generating 
lesions using surgical, thermal, electrolytic, and toxicant means for scientific 
study of the effect of central nervous system injury on brain function. In addition 
to identifying anatomical regions of interest, scientists using early lesioning 
techniques began to recognize the behavioral similarities to known human 
neurological disorders and began to recognize the value of animal models. 
In general, however, the overall utility of an animal model for a particular 
disease is often dependent on how closely the model replicates all or part of the 
human condition. In PD and related parkinsonian disorders, there now exist a 
variety of animal models, including new invertebrate models, each of which 
makes a unique contribution to our understanding of the human condition. These 
models have been developed in a wide variety of species (i.e., mouse, rat, cat, 
and non-human primate and many other species including Drosophila) using a 
variety of techniques including: 
1. Surgical lesioning 
2. Administration of pharmacological agents 
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3. Administration of neurotoxicants 
4. Development of transgenic animals [7]. 
Models of PD 
1. Pharmacological-Induced Models of Parkinson‘s disease 
 Reserpine 
 ɑ-Methyl-para-Tyrosine (AMPT) 
2. Neurotoxicant-Induced Models of Parkinson‘s Disease 
 6-Hydroxydopamine (6-OHDA) 
 MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) 
 Methamphetamine 
 Rotenone 
 Intranigral Infusion of Iron 
 1-Benzyl-1,2,3,4-tetrahydroisoquinoline  
 Lipopolysaccharide  
 Quinolinic Acid Lesioning  
3. Genetic Models of Parkinson‘s Disease 
 Spontaneous Rodent Models for Parkinson‘s Disease 
 Transgenic Mouse Models 
(a) ɑ-Synuclein 
(b) β-Synuclein 
(c) Parkin 
(d) UCH-1 
 Invertebrate Models with ɑ-Synuclein and Parkin 
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Toxin-Induced Models of Parkinson’s disease 
Among the various accepted experimental models of PD, neurotoxins 
have remained the most popular tools to produce selective neuronal death in 
both in vitro and in vivo systems. Neurotoxins reviewed here are thought to kill 
dopaminergic neurons; they all produce specific clinical or neuropathological 
abnormalities that make them different from each other [8]. Among all neurotoxins, 
rotenone is selectively used in many studies due to the selective inhibition of 
complex-I mitochondrial electron transport chain (ETC). 
Rotenone neurotoxin 
Rotenone is a naturally occurring complex ketone pesticide derived from 
the roots of Lonchocarpus species. It is highly lipophilic and can rapidly cross 
cellular membranes without the aid of transporters, including the BBB. Rotenone 
is a strong inhibitor of complex I, which is located at the inner mitochondrial 
membrane and protrudes into the matrix. Rotenone model of PD, which 
substantiated involvement of pesticide exposure and systemic complex I 
dysfunction in PD etiology.  
In addition to being a common pesticide, rotenone is a high-affinity 
inhibitor of complex I of the mitochondrial ETC. Although rotenone caused 
uniform complex I inhibition throughout the brain, rotenone-treated rats 
demonstrated many characteristics of PD, including selective nigrostriatal 
dopaminergic degeneration, formation of ubiquitin and ɑ-synuclein-positive nigral 
inclusions, and motor deficits [9]. 
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Mechanism of rotenone 
Rotenone is a powerful selective mitochondrial complex I inhibitor, which 
can cause oxidative stress and lead to selective degeneration of striatal–nigral 
dopaminergic neurons [10]. Besides complex I inhibition, nitrative stress, increased 
nitric oxide (NO) and malondialdehyde (MDA) levels, aggregation of alpha-
synuclein (SNCA) and polyubiquitin, activation of astrocytes and microglial cells, 
inflammatory reaction, glutamate excitotoxicity, and neuron apoptosis are 
involved in the mechanisms of rotenone-evoked Parkinsonism. 
Oxidative stress 
In a variety of cellular sources and cultured brain slices, complex I 
inhibition, overgeneration of reactive oxygen and reactive nitrogen species, 
shifting respiration to a more anaerobic state and lipid peroxidation are reportedly 
potent contributors to rotenone neurotoxicity [11]. 
Fig.No.5: Rotenone neurotoxicity – Oxidative stress 
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Behavioral and Pathological Features of rotenone model 
1) Parkinsonism (bradykinesia, fixed posture, and rigidity) 
2) Good response to L-DOPA and dopamine agonists 
3) Loss of Tyrosine hydroxylase neurons and DA-content in nigrostriatal region 
4) ɑ-Synuclein-positive inclusions, resemblance to true Lewy body  
5) Loss of myenteric neurons 
Advantages  
 Easily crosses the BBB 
 Inhibits electron transport Chain (ETC) complex I 
 Upregulation of NADPH oxidase 
 Microglial activation 
 Highly lipophilic  – crosses the blood brain barrier 
 It will also inhibit proteasomal activity [12].  
CURRENT TREATMENTS FOR PD  [13]   
Classification of drugs 
1. Drugs which replace DA 
Levodopa 
(a) peripheral dopa decarboxylase inhibitors. 
Carbidopa, benserazide 
2. Inhibitors of dopamine metabolizing enzymes 
(a) drugs that inhibits catechol-o-methyl transferase 
Tolcapone, Entacapone 
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(b) Drugs that inhibits Monoamine oxidase B 
Selegiline, Rasalgine 
3. Drugs that mimic DA (DA agonists) 
(a) D2 agonist and Partial D1 antagonist 
Bromocriptine, Lisuride 
(b) Both D1 and D2 agonists 
Pergolide 
(c) Selective D2 agonists 
Praipexzole, Ropinirole 
4. Muscarinic acetylcholine receptor antagonists  
Benzatropine, Trihexyphenidyl, Diphenhydramine 
5. Drugs that release DA 
Amantadine 
Levodopa 
Levodopa (L-dopa), the metabolic precursor of dopamine, is the single 
most effective agent in the treatment of PD. Both its therapeutic effect and 
adverse effects result from the decarboxylation of levodopa to dopamine by 
dopa-decarboxyase. Dopamine cannot pass through Blood-brain barrier, but L-
dopa can. The passage of L-dopa across BBB is an active process, mediated by 
a carrier specific for aromatic amino acids. 
The dopamine produced is responsible for the therapeutic effectiveness of 
the drug in PD. The decarboxylation of L-dopa to DA in brain, takes place within 
the presynaptic terminals of dopaminergic neurons in the striatum.  
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In practice, L-dopa is almost always administered with peripheral dopa 
decarboxylase inhibitors (e.g.) carbidopa, benserazide, that do not penetrate into 
the CNS. These drugs inhibit the decarboxylation of L-dopa in periphery and 
increase the amount of L-dopa crossing BBB up to 10-fold.  
L-dopa produces dramatic effects on all the signs and symptoms of PD. 
The degree of improvement in tremor, rigidity and bradykinesia is nearly 
complete in early phase of treatment. Some dopamine released will be stored in 
vesicles and that the improvement is uniform. Some symptoms like dysphagia, 
cognitive decline, etc. are not improved. 
The adverse effects of L-dopa are mainly due to its conversion to 
dopamine in the peripheral mainly including the alteration of blood pressure, 
ionotropic effect on heart, inhibition of prolactin secretion, nausea, vomiting, 
anorexia, postural hypotension, palpitation, arrhythmia, etc. Chronic adverse 
effects may include hallucinations, insomnia, restlessness, delusions, etc.  
But the severe effect of chronic use of L-dopa in PD patients include 
dyskinesia and on/off phenomena. This is largely due to inability of the 
dopaminergic neurons to reuptake, store and later release the dopamine formed 
from administered L-dopa. Also it is important to note that the dopamine, thus 
converted from L-dopa, undergoes oxidative metabolism further generates large 
quantities of free radicals which accelerate the neuronal death due to oxidative 
stress.  
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Inhibitors of dopamine metabolizing enzymes 
 Catechol-o-methyl transferase and monoamine oxidase B are the 
enzymes mainly involved in the metabolism of dopamine. Hence inhibition of 
these enzymes helps in increasing the available concentration of dopamine 
leading to alleviation of symptoms in PD. Tolcapone and entacapone are durgs 
that inhibit Catechol-o-methyl transferase and drugs like selegeline, rasalgeline, 
etc inhibit monoamine oxidase B. Even though these drugs are slightly better in 
producing side effects when compared to L-dopa, but do produce effects like 
hepatotoxicity, anxiety, insomnia, etc.   
Drugs that mimic DA (DA agonists) 
 Drugs that mimic the effects of dopamine at the dopaminergic receptors 
are a good alternatives to L-dopa. They directly activate the receptor without any 
enzyme mediation for activation. They also do not depend on the functional 
ability of the dopaminergic nerves in the nigrostriatum i.e., ability to store and 
release dopamine. There is no free radical formation which would further 
degenerate the nerves. But chronic use of these agents too is limited by the 
appearance of side effects like cardio vascular disorders, somnolence, nausea, 
etc.  
Muscarinic acetylcholine receptor antagonists  
 In a normal individual there exists a fine balance between the stimulatory 
cholinergic and inhibitory dopaminergic systems in the nigrostriatum. 
Degeneration of dopaminergic neurons results in loss of balance and cholinergic 
system contributing the symptoms of PD like tremors, etc. Hence muscarinic 
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antagonists are used to reduce the cholinergic stimulation and thereby bringing 
back the balance. The drugs include trihexyphenidyl, benztropine, 
diphenhydramine, etc. Most troublesome side effects like sedation, mental 
confusion, etc. ensues.  
Drugs that release DA 
 Amantadine, an antiviral agent, is useful in the treatment if PD and  acts 
by altering the dopamine release. Side effects include dizziness, lethargy, sleep 
disturbance, etc.  
Alternative medicine/Therapy 
This means a replacement for mainstream medicine. Alternative medicine 
can have their own theories of disease and methods of diagnosis, as well as 
different treatments.  
Acupuncture: 
Acupuncture is part of traditional Chinese medicine and has been used for 
thousands of years. In Parkinson‘s, it may be helpful mostly for pain control. It is 
based on the premise that disease states are characterized by imbalances in 
flow of energy, and that insertion of needles along various points within energy 
channels can restore balance and health. Acupuncture appears to be safe, and 
many patients anecdotally describe benefit but there is not sufficient evidence to 
recommend it to patients with PD[14].  
Alexander technique: 
Alexander technique was invented by an actor, Frederick Alexander 
(1869–1955). He developed the method to treat himself when he developed 
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problems with his voice. Later, he taught the system to others. Alexander 
technique trains you to think carefully about the way you use your muscles, 
recognizing and releasing muscle tension. There are only a few good scientific 
studies of Alexander technique. In one of these, it helped people suffering from 
back pain. In Parkinson‘s, it might help with co-ordination, balance, pain, fatigue 
and tremor [14]. 
Aromatherapy: 
Aromatherapy uses oils made from a huge variety of flowers and plants. 
These ‗essential oils‘ are usually massaged into your skin. They can also be 
inhaled or used in creams or in the bath. The theory is that essential oils have 
chemical properties that can ha ve all sorts of effects on both mind and body. 
People use aromatherapy for stress, pain, insomnia and depression and many 
other ailments. Some people see it more as a relaxing treat [14]. 
Ayurveda: 
Ayurveda originates from India and is derived from ancient religious and 
philosophical writings called the Vedas. Ayurveda literally means ‗the knowledge 
of life‘.  Ayurveda as kampavata, kampa meaning tremor and vata representing 
one of the dhosa, resembles Parkinson disease in its features. A common 
Ayurvedic treatment for kampavata comprises prominently of plant drugs 
Ashwagandha (Withania somnifera root) and Atmagupta (Mucuna pruriens 
seeds). Mucuna pruriens is a legume plant, known as ‗velvet bean‘, which grows 
in tropical Asia and tropical Africa where it is native. It is used as food, but also in 
traditional medical practices [15].  
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Parkinson‘s is co-related with kampavata in Ayurveda. In old age vata 
dosha is more predominant in the body. This vata relocates in the brain and dries 
up the brain cells leading to tremors and instability. Parkinsons disease reflects 
massive vitiation of vata which occupies almost all channels of body. Weak 
digestive fire, disturbed digestion and presence of toxins are generally observed 
in the patient at gastrointestinal as well as cellular levels, which provide 
conducive environment for vitiation of vata. Digestive herbs, in conjunction with 
nerve tonics are administered to restore digestive function both in the gastro 
intestinal tract and at a cellular level. Specific diets and regimen are advised. 
Mucuna pruriens has been used by Ayurvedic physicians in the past for 
the treatment of PD, it was felt that it should be reevaluated using modern 
methods of testing. There is a clear trend in favor of alternative medicine [16].   
Herbal medicines 
Herbal products for PD have been used worldwide in traditional medicine. 
Practitioners and patients employ HM as an adjuvant therapy of conventional 
treatment for the purpose of reducing dose of dopaminergic drugs, adverse event 
related to prolonged usage of dopaminergic agents and improving PD  
symptoms [17]. The herbs which show the significant effect in treating 
Parkinsonism are mentioned below: 
 Acanthopanax senticosus Harms (family: Alariaceae) 
 Withania somnifera (Family: Solanaceae) 
 Uncaria rhynchophylla (family: Rubiaceae) 
 Nardostachys jatamansi (Family: Valirenaceae) 
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 Chrysanthemum morifolium (Family: Asteraceae) 
 Cassiae semen (family:Leguminosae) 
 Anemopaegma mirandu (family:Bignoniaceae) 
 Hypericum perforatum (Family:Hpericaceae) 
 Gastrodia elata Blume (Family: Orchidaceae) 
 Centella asiatica (Family: Umbelliferae) 
 Thuja orientalis (Family: Cupressaceae) 
 Mucuna pruriens (Family: leguminosae) 
 Ginkgo biloba (Family: Ginkgoaceae) 
 Plumbago scandens (Family: Plumbaginaceae) 
 Bacopa monniera (Family: Scrophulariaceae) 
 Pueraria thomsonii ( Family:Fabaceae) 
A huge heterogeneity in the herbal composition, drug formulation, dose, 
duration, combined therapy and control interventions was observed, which were 
the main obstacles to estimate the general effect size of herbal remedies [18]. 
Cymbopogon flexuosus 
Cymbopogon flexuosus (Family: Poaceae), the plant used in the study, is 
available all over India, Sri Lanka, Burma and Thailand [19].The plant has been 
used in traditional system of medicine for the treatment of fever, stimulant and 
used as a flavouring agent, carminative and perfumery [20]. 
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PLANT PROFILE 
Cymbopogon flexuosus (Nees ex Steud.) Will. Watson 
Family: Poaceae (Gramineae) 
Common names:  Cochin grass 
Malabar grass 
East Indian lemongrass 
France Indian verbena 
Vernacular names: 
English: East Indian lemon grass 
Malayalam: Chukkunaripullu / Inchipullu 
Tamil: Karpoorapullu 
Distribution: 
India, Sri Lanka, Burma and Thailand 
Chemical constituents: 
The chemical composition of C. flexuosus oil has been reported. Some 
common constituents found in Cymbopogon flexuosus oil (CFO) such as geraniol 
(20%), geranyl acetate (12%), limonene (3.5%), ɑ-bisabolol (8.4%) [21]. 
The essential oil of Cymbopogon flexuosus is consisted mainly of citral (75-85%) 
which is mixture of geranial (citral a) and neral (citral b). 
Other compounds present in prominent amounts reported in numerous 
previous studies are: Citronellal (0.37-8.04%), Citronellol (0.44-4.58%), 
Citronellyl acetate (1.2-3.6%), methyl eugenol (20.0%) and myrcene (0.1-14.2%) 
[19]. 
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Fig.No.6: Parts of Cymbopogon flexuosus (lemon grass) 
Parts Used: 
Essential parts – Stalks and Leaves  
Description: 
It is a tall, fast-growing, lemon scented, perennial grass reaching a height 
of 1.5m. It has distinct, dark-green foliage and also produces seed [22]  
Traditional uses: 
Oil is used as stimulant, flavouring agent, as a carminative and also in 
perfumery. Citral is used in the synthesis of β-ionone from which vitamin A is 
prepared [20]. 
 
Cymbopogon 
flexuosus 
Lemon 
grass oil 
Stalks 
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Reported activities: 
Limonene and borneol present in the essential oil of C. flexuosus have 
anaesthetic properties [19]; antimicrobial [22, 23]; anticancer activity [24]; 
immunostimulatory and analgesic and anti- inflammatory [25] properties. 
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REVIEW OF LITERATURE 
Anusha et al., (2017) [25] investigated and reported the protective role of 
apigenin on rotenone induced rat model of Parkinson‘s disease: Suppression of 
neuroinflammation and oxidative stress mediated apoptosis. Apigenin (AGN), a 
non-mutagenic flavone found in fruits and vegetables, exhibits a variety of 
biological effects including anti-apoptotic, anti-inflammatory, and free radical 
scavenging activities. Unilateral stereotaxic infusion of ROT caused the loss of 
tyrosine hydroxylase (TH) immunoreactivity in striatum and substantia nigra. The 
mRNA expression of inflammatory markers and neurotrophic factors was 
quantified by reverse transcriptase polymerase chain reaction (RT-PCR). 
Administration of AGN significantly attenuated the upregulation of NF- κB gene 
expression in ROT induced group and prevented the neuroinflammation in 
substantia nigra pars compacta (SNpc).AGN exerts its neuroprotection in ROT 
model of PD and may act as an effective agent for treatment of PD. 
Badawi et al., (2017) [26] studied and reported the Sitagliptin and liraglutide 
reversed nigrostriatal degeneration of rodent brain in rotenone-induced 
Parkinson‘s disease. Their study investigated the possible relationship between 
pro-inflammatory cytokines and programmed nigral neuronal death in rotenone 
model of Parkinson‘s disease (PD). Sitagliptin and liraglutide efficacy to inhibit 
the inflammatory-apoptotic degenerative process were investigated. Sitagliptin 
(30 mg/kg/day, p.o) and liraglutide (50 lg/kg, s.c.) showed statistically significant 
(p < 0.05) effect on behavioral activity. Where, both doses improved the motor 
performance significantly in comparison with other doses in both cylindrical and 
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catalepsy tests. Sitagliptin and liraglutide represent a promising strategy to 
mitigate the progression of PD by their anti-inflammatory, anti-apoptotic 
neurotrophic and neurogenic mechanistic activities. 
Darbinyan et al., (2017) [1] investigated and reported the Rotenone impairs 
hippocampal neuronal activity in a rat model of Parkinson‘s disease. Interactions 
between the dopaminergic systems and the hippocampus in synaptic plasticity 
and behavior are found. The Rotenone-induced animal model is commonly used 
in research studies involved in PD. Administration of rotenone causes alterations 
of electrical neuronal activity. Dose-dependent reduction of evoked neural activity 
and a reduction in firing strength were found in the hippocampus. Behaviorally, 
Rotenone rats showed a more consistent decrease in rearing across the 3 
weeks, compared with animals in the control group. Thus, rotenone causes 
changes in hippocampal electrical activity and behavioral changes. 
Adukwu et al., (2016) [21] performed and reported the antimicrobial activity, 
cytotoxicity and chemical analysis of lemongrass essential oil (Cymbopogon 
flexuosus) and pure citral. To determine the antimicrobial effects of lemongrass 
oil (C. flexuosus) and to determine cytotoxic effects of both test compounds on 
human dermal fibroblasts. Antimicrobial susceptibility screening was carried out 
using the disk diffusion method. Antimicrobial resistance was observed in four of 
five Acinetobacter baumannii strains with two strains confirmed as multi-drug-
resistant (MDR). 
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Dhanalakshmi et al., (2016) [27] examined and reported Vanillin Attenuated 
Behavioural Impairments, Neurochemical Deficts, Oxidative Stress and 
Apoptosis against Rotenone Induced Rat Model of Parkinson‘s Disease. Vanillin 
(4-hydroxy-3-methoxybenzaldehyde), a pleasant smelling organic aromatic 
compound, is widely used as a flavoring additive in food, beverage, cosmetic and 
drug industries. It is reported to cross the blood brain barrier and also displayed 
antioxidant and Neuroprotective activities. Rotenone treatment exhibited motor 
and non-motor impairments, neurochemical deficits, oxidative stress and 
apoptosis, whereas oral administration of vanillin attenuated the above-said 
indices. Akinesia, catalepsy and open field test are normally performed to assess 
the delay in initiating a movement, rigidity and locomotion and exploratory like 
behavior respectively in experimental rodents. Intraperitonial administration of 
rotenone showed a significant impairment in akinetic movement, cataleptic 
ability, locomotion activity as compared to control rats. In their study, Depletion of 
brain dopamine levels in rotenone treated rats resulted in behavioral anomalies 
as seen in PD. Enhancement of striatal dopamine and its metabolite levels by 
vanillin clearly indicate the efficiency of vanillin in protecting dopaminergic 
neurons. 
Gupta et al., (2016) [22] investigated and reported a study on antimicrobial 
activities of essential oils of different cultiviers of lemongrass (Cymbopogon 
flexuosus). Essential oils were isolated from one month old plants by hydro-
distillation in mini Clevenger apparatus for 2 h. Antimicrobial activities were 
determined by agar well diffusion method. Lemongrass oils exhibited strong 
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antimicrobial activity against all the microbes except E coli. The study revealed 
strong antimicrobial potential of the essential oil against pathogenic microbial 
strains which may be of high clinical importance in future. 
Cortes et al., (2015) [28] investigated and reported Protective efficacy of P7C3-
S243 in the 6-hydroxydopamine model of Parkinson‘s disease. There are 
currently no therapeutic options for patients with Parkinson‘s disease that prevent 
or slow the death of dopaminergic neurons. We have recently identified the novel 
P7C3 class of neuroprotective molecules that blocks neuron cell death. After 
unilateral injection of 6-OHDA into the median forebrain bundle, rats were 
assessed for behavioral function in the open field, cylinder test, and 
amphetamine-induced circling test. Thereafter, their brains were subjected to 
neurochemical and immune histochemical analysis of dopaminergic neuron 
survival. Analysis was conducted as a function of treatment with P7C3 
compounds, with administration initiated either before or after 6-OHDA exposure. 
When P7C3-S243 administration was initiated after 6-OHDA exposure, rats also 
showed protective efficacy in all measures, which included blocking 
dopaminergic neuron cell death in ipsilateral substantia nigra pars compacta, 
preservation of dopamine and its metabolites in ipsilateral striatum, and 
preservation of normal motor behavior. 
Desai et al., (2014) [29] investigated and reported the Modeling and optimization 
studies on extraction of lemongrass oil from Cymbopogon flexuosus (Steud.) 
Wats. Optimization studies for the extraction of essential oil from the leaves of 
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lemongrass by hydro-distillation. The models based on partitioning 
thermodynamics and kinetic desorption were studied to understand the extraction 
behaviour. The process was found to be influenced by the initial desorption step, 
described by the two-site kinetic desorption model. The optimum conditions, 
using the Taguchi method, were obtained as: 1:14 (w/w) solid to water ratio, 25 
mm size of the plant material, extraction time of 1.5 h and 500 W powers. 
Qualitative analysis of essential oil was performed and the maximum amount of 
citral (83.24%) was obtained under optimized condition. 
Mahindra et al., (2014) [30] investigated and discussed about Microwave 
Assisted Extraction of Lemongrass Oil. Lemongrass is an important member of 
the grass family grown mostly as a source of citral in its essential oil, which is 
widely for the production of artificial vitamin A. Essential oil of lemongrass was 
extracted by microwave-assisted hydro-distillation (MAHD) and the individual 
effects of process parameters; microwave power and irradiation time. Results 
showed that oil yield increases with increasing microwave power and irradiation 
time the maximum oil yield in MAHD was 1.72% for 90 minutes. 
Samim et al., (2014) [31] investigated and reported Neuroprotective Effect of 
Ocimum sanctum Linn on Rotenone Induced Parkinsonism in Rats. Experimental 
PD was induced by administration of rotenone, a neurotoxin which developed all 
the essential features of PD. PD is attributed to oxidative and inflammatory stress 
and hence drugs targeting these pathways hold promise as neuro-therapeutics. 
The behavioural alterations were evaluated by the open field test, pole test and 
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rotarod test. Biochemical changes were assayed by estimating MDA, GSH and 
SOD. Histopathological study of the substantia nigra (SN) was also done. 
Treatment with lower and high dose of OS reversed the locomotor deficits and 
biochemical alterations due to rotenone which were supported by 
histopathological studies. 
Sharma and Deshmukh, (2014) [32] examined and reported the Vinpocetine 
attenuates MPTP-induced motor deficit and biochemical abnormalities in wistar 
rats. Up-regulation in phosphodiesterase 1 (PDE1) expression and decreased 
levels of cyclic nucleotides (cAMP and cGMP) have been reported in patients 
and experimental animal models of Parkinson‘s disease (PD). 
Phosphodiesterase (PDE) inhibitors have been reported to be beneficial in 
cognitive and motor deficit states. The study is designed to investigate the effect 
of vinpocetine, a PDE1 inhibitor in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine 
(MPTP)-Induced experimental PD-like symptoms in rats. Movement 
abnormalities were assessed by a battery of behavioral tests. 
Ittiyavirah and Ruby, (2014) [33]  examined the effect of hydro alcoholic root 
extract of Plumbago zeylanical (PZE)alone and it‘s combination with aqueous 
leaf extract Camellia sinensis (AECS)on rotenone induced Parkinsonism. The 
synergistic effect with AECS were assessed by the ex vivo antioxidant assays by 
measuring the various enzymes in the striatum region of brain such as 
Glutathione, Lipid peroxidation, Catalase and Superoxide dismutase. The various 
behavioral parameters analyzed were rearing, self-grooming, ambulation activity 
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using open field apparatus and muscle rigidity using bar test. The administration 
of rotenone produced motor dysfunctions like catalepsy and muscle rigidity along 
with a reduction in locomotor activity.  
Tyagi et al., (2014) [34] investigated and reported the possible role of GABA-B 
receptor modulation in MPTP induced Parkinson‘s disease in rats. Accumulating 
evidence strongly suggests that gamma amino butyric acid (GABA) receptors 
play a crucial role in the pathogenesis of Parkinson‘s disease (PD). The study 
investigate the role of GABA-B receptor modulation in experimental models of 
MPTP-induced PD. Different behavioural tasks were performed  and biochemical 
parameters were estimated, post treatment with baclofen significantly improved 
the motor abnormalities and attenuated the oxidative damage and neuro-
inflammation in MPTP treated rats. CGP35348, GABA-B receptor antagonist, 
reversed the protective effect of baclofen GABA-B receptor play role in the 
neuroprotection. 
Khurana and Asmita, (2013) [35] investigated and studied the ameliorative effect 
of Sida cordifolia in rotenone-induced oxidative stress model of Parkinson‘s 
disease. The study focused on the evaluation of aqueous extract, and its different 
fractions), against rotenone induced biochemical, neurochemical, 
histopathological and behavioral alterations in a rat model of Parkinson‘s disease 
(PD). Sida cordifolia is an important medicinal plant of Ayurvedic system of 
medicine, containing a number of poly-phenolic compounds. There is ancient 
Ayurvedic relevance for the use of this plant in the treatment of PD, the plant 
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possesses significant in vitro and ex vivo anti-oxidant activity and encouraged its 
evaluation for the possible beneficial effect in neurodegenerative diseases based 
on its traditional use. As oxidative stress plays an important role in generation of 
rotenone-induced PD pathology, it is worth to explore the beneficial effect of this 
antioxidant plant in rotenone-induced oxidative stress model of PD. 
Ain et al.,(2013) [36] investigated and reported an experimental design approach 
for the extraction of lemongrass (Cymbopogon citratus) oleoresin using 
pressurised liquid extraction (PLE). Extraction of lemongrass oleoresin was 
successfully optimised using Pressurised Liquid Extraction (PLE). Character 
impact compounds; neral, geranial and geraniol which constituted 72% oleoresin, 
were monitored during this optimisation study by using GCMSD. Based on 
maximum extraction of these compounds, the optimised operating conditions for 
PLE were a temperature of 167°C, a pressure of 1203 psi and a static time of 
20.43 min. The quality of PLE extract was compared with conventional extraction 
methods, hydro-distillation and Soxhlet extraction. investigated and reported the 
Hydro-distillation of Essential Oil from Cymbopogon flexuosus. Hydro-distillation 
is a potentially useful method to extract essential oil from various plant materials 
and was used to separate essential oil from Cymbopogon flexuosus 
(lemongrass). The yield is dependent on various parameters like weight of raw 
material, volume of water, size of raw material and nature of raw material. The 
optimized conditions for the extraction were 50 g of raw material, 500 ml of water 
volume, plant size of 25 mm, and the yield obtained was 1.04 percent. The loss 
of about nine percent essential oil was observed during drying of leaves of 
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lemongrass. Composition of the essential oil was analyzed by GC-MS and higher 
amount of oxygenated compounds, mainly citral, was found in each sample. 
Swathi et al., (2013) [37] investigated and reported the evaluation of rotenone 
induced Parkinson‘s disease on glutamate metabolism and protective strategies 
of Bacopa monnieri. The Neuroprotective effect of Rotenone (RT) induced 
Parkinson‘s disease (PD) with particular reference to glutamate metabolism in 
different regions of rat brain. The rats were divided into four groups of six in each, 
group 1 received Saline water, and group 2 received RT through i.p. route for 60 
days to induce PD. The BM extract was given orally 20 days before induction of 
the PD to group 3 and group 4 received Levodopa (LD) orally, referred as drug 
control. The levels of glutamate content, Glutamate dehydrogenase (GDH), 
Glutamine synthetase (GS) and Glutaminase were measured. Glutamine content 
and activity levels of GDH, GS were significantly depleted and elevated 
glutaminase activity was found in the different brain regions of rat during RT 
induced PD when compared to controls rats.  
Desai and Parikh, (2012) [38] studied and reported the Hydrotropic Extraction of 
Citral from Cymbopogon flexuosus (Steud.) Wats. A novel technique for the 
extraction of citral from the leaves of Cymbopogon flexuosus (Steud.) Wats. 
Using hydrotropic solutions (sodium salicylate and sodium cumene sulfonate) 
was investigated. The yield of citral was dependent on the concentration of 
hydrotrope, solid loading, temperature, and size of the plant material. Using the 
Taguchi method, the extraction was optimized, and both the hydrotropes gave 
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the highest yield of citral at a concentration of 1.75 M, 5% solid loading, a 
temperature of 30 °C, and a size of 0.25 mm of the plant material. Using 
hydrotropic extraction, citral could be extracted under normal operating 
conditions, and the use of traditional organic solvents could be eliminated. As a 
simple and environmentally friendly technique, hydrotropic extraction could be 
utilized for the extraction of bioactive compounds from plants. 
Riddle et al., (2012) [39] explored and reported the Pramipexole and 
methamphetamine-induced reward-mediated behavior in a rodent model of 
Parkinson‘s disease and controls. Pramipexole (PPX) is a dopamine agonist that 
is FDA-approved for treatment of motor dysfunction in Parkinson‘s disease and 
restless leg syndrome. In a subpopulation of treated patients, PPX can lead to 
impulsive–compulsive disorders including behavioral addictions and dopamine 
dysregulation syndrome, a phenomenon that mirrors drug addiction. 
Methamphetamine (meth) and saline served as positive and negative controls, 
respectively. To model Parkinson‘s disease, the neurotoxin 6-OHDA was injected 
bilaterally into the dorsolateral striatum. The resulting lesions were verified 
functionally using a forelimb adjusting step and post mortem 
immunohistochemical staining of striatal tyrosine hydroxylase. 
Adukwu et al., (2011) [40] investigated and reported the anti-biofilm activity of 
lemongrass (Cymbopogon flexuosus) and grape fruit (Citrus paradisi) essential 
oils against five strains of Staphylococcus aureus. Antimicrobial susceptibility 
screening was carried out using disk diffusion method.  
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Khuwaja et al., (2011) [41] examined and reported the Neuroprotective effects of 
curcumin on 6-hydroxydopamine-induced Parkinsonism in rats: Behavioral, 
neurochemical and immunohistochemical studies. Curcumin, the active principle 
of turmeric used in Indian curry is known for its antitumor, antioxidant, 
antiarthritic, anti-ischemic and anti-inflammatory properties and might inhibit the 
accumulation of destructive beta-amyloid in the brains of Alzheimer's disease 
patients. A Parkinsonian model in rats was developed by giving 6- 
hydroxydopamine (10μg/2μl in 0.1% ascorbic acid–saline) in the right striatum. A 
significant protection of lipid peroxidation, glutathione, glutathione peroxidase, 
glutathione reductase, superoxide dismutase, catalase, tyrosine hydroxylase and 
D2 receptor binding was observed in the striatum of lesioned group animals 
pretreated with 80mg/kg body weight of curcumin for 21 days as compared to 
lesion group animals. No significant alterations in behavior and biochemical 
parameters were observed in sham group animals. Their study indicates that 
curcumin, which is an important ingredient of diet in India and also used in 
various systems of indigenous medicine, is helpful in preventing Parkinsonism 
and has therapeutic potential in combating this devastating neurologic disorder. 
Parikh and Desai, (2011) [42] investigated and reported the Hydro-distillation of 
Essential Oil from Cymbopogon flexuosus. Hydro-distillation is a potentially 
useful method to extract essential oil from various plant materials and was used 
to separate essential oil from Cymbopogon flexuosus (lemongrass). The yield is 
dependent on various parameters like weight of raw material, volume of water, 
size of raw material and nature of raw material. The optimized conditions for the 
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extraction were 50 g of raw material, 500 ml of water volume, plant size of 25 
mm, and the yield obtained was 1.04 percent. The loss of about nine percent 
essential oil was observed during drying of leaves of lemongrass. Composition of 
the essential oil was analyzed by GC-MS and higher amount of oxygenated 
compounds, mainly citral, was found in each sample. 
Swarnkar et al., (2011) [43] investigated and reported the Rotenone induced 
neurotoxicity in rat brain areas: A histopathological study. Rotenone a pesticide is 
known to induce neurotoxicity. Rotenone induced biochemical changes and 
cerebral damage in brain areas with neuromuscular coordination in rats. This  
study involves investigation of rotenone induced histopathological changes in the 
brain areas, striatum (STR) and substantia nigra (SN) using HE (hematoxylin and 
eosin) and CV (Cresyl Violet) staining after 1, 7, and 14 day of unilateral 
intranigral administration of rotenone (3, 6 and 12µg/5µl) in adult male SD rats. 
The study inferred rotenone causes neuronal damage which is evident by 
histopathological changes, impaired neuromuscular coordination and 
biochemical changes.  
Chandrashekar and Prasanna, (2010) [24] investigated and reported Analgesic 
and Anti-inflammatory Activities of the Essential oil from Cymbopogon flexuosus. 
The anti-inflammatory activity was studied using acute or chronic treatments in 
rats. Analgesic effect of the essential oil was evaluated in acetic acid induced 
writhing and tail flick model. The essential oil exhibited significant anti-
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inflammatory activities in the acute carrageenan- induced rat paw edema and the 
chronic granuloma pouch models.  
Cannon et al., (2009) [44] performed and reported A highly reproducible rotenone 
model of Parkinson's disease. The systemic rotenone model of Parkinson's 
disease (PD) accurately replicates many aspects of the pathology of human PD 
and has provided insights into the pathogenesis of PD. The major limitation of the 
rotenone model has been its variability, both in terms of the percentage of 
animals that develop a clear-cut nigrostriatal lesion and the extent of that lesion. 
Male Lewis rats in three age groups (3, 7 or 12–14 months) were administered 
rotenone (2.75 or 3.0 mg/kg/day) in a specialized vehicle by daily intraperitoneal 
injection. All rotenone-treated animals developed bradykinesia, postural 
instability, and/or rigidity, which were reversed by apomorphine, consistent with a 
lesion of the nigrostriatal dopamine system. Animals were sacrificed when the 
PD phenotype became debilitating. Rotenone treatment caused a 45% loss of 
tyrosine hydroxylase-positive substantia nigra neurons and a commensurate loss 
of striatal dopamine.  
Sharma et al., (2009) [45] investigated and reported anticancer activity of an 
essential oil from cymbopogon flexuosus. The essential oil from a lemongrass 
variety of cymbopogon flexuosus was studied for its in vitro cytotoxicity against 
twelve human cancer cell lines. The in vivo anticancer activity of the oil was also 
studied using both solid and ascetic Ehrlich and Sarcoma-180 tumor models in 
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mice. In addition, the morphological changes in tumor cells were studied to 
ascertain the mechanism of cell death. 
Woodley et al., (2008) [46] investigated and reported the Enhanced function in 
the good forelimb of hemi-parkinson rats: Compensatory adaptation for 
contralateral postural instability? Postural instability is a major deficit in 
Parkinson's disease that is resistant to levodopa therapy and contributes to the 
risk of falling. One forelimb at a time, to normal rats as well as rats extensively 
depleted of dopamine by unilateral infusion of 6- hydroxydopamine (6-OHDA, 
given in the medial forebrain bundle) to produce a hemi-parkinsonian syndrome. 
The 6-OHDA rats showed severe postural instability in the impaired forelimb, but 
unexpectedly showed enhanced function in the non-impaired forelimb. The data 
suggest that the intact hemisphere may undergo rapid reorganization subsequent 
to unilateral dopamine depletion, which allows for compensatory function of the 
―intact‖ limb.  
Ahmad et al., (2005) [47] studied and reported Neuroprotective effects of 
Withania somnifera on 6-hydroxydopamine induced Parkinsonism in rats. The 
anti-parkinsonian effects of Withania somnifera extract, which has been reported 
to have potent anti-oxidant, anti-peroxidative and free radical quenching 
properties in various diseased conditions. 6-Hydroxydopamine (6-OHDA) is one 
of the most widely used rat models for Parkinson's disease. There is ample 
evidence in the literature that 6-OHDA elicits its toxic manifestations through 
oxidant stress. 6-OHDA has been reported to cause its dopaminergic toxicity by 
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the process of lipid peroxidation and oxidant stress and there are many reports 
whereby antioxidants have been implicated in the protection against 6-OHDA 
toxicity. 
Panov et al., (2005) [47] examined and reported the Rotenone Model of 
Parkinson Disease multiple brain mitochondria dysfunctions after short term 
systemic rotenone intoxication. Chronic infusion of rotenone (Rot) to Lewis rats 
reproduces many features of Parkinson disease. Rot (3 mg/kg/day) was infused 
subcutaneously to male Lewis rats for 6 days using Alzet minipumps. Control rats 
received the vehicle only. Rotenone, when introduced in vivo, binds specifically 
to the mitochondrial Complex I (NADH:ubiquinone oxidoreductase) all over the 
brain.  
Bashkatora et al., (2004) [48] investigated and reported the chronic 
administration of rotenone increases levels of nitric oxide and lipid peroxidation 
products in rat brain. The complex I inhibitor rotenone is a neurotoxin that has 
been proposed to induce Parkinson-like degeneration. NO and TBARS were 
increased in the frontal cortex and in the striatum. Behaviorally, the rats exhibited 
akinesia and rigidity in the catalepsy test. These results show that chronic 
administration of rotenone over a long period is capable of increasing NO and 
TBARS in the cortex and striatum and mimics Parkinson‘s disease (PD)-like 
behavioral symptoms that are akinesia and rigidity in rats. 
Brown et al., (1999) [49] investigated and reported the Differences in Measures of 
Exploration and Fear in MHC-Congenic C57BL/6J and B6-H-2K Mice. Examine 
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the strain and sex differences in MHC-congenic C57BL/6J and B6-H-2K mice 
with respect to exploration and fear motivated behaviors in the elevated plus 
maze, the elevated zero maze, and the open field. In the elevated plus maze and 
elevated zero maze, C57BL/6J mice spent more time in the open areas than B6-
H-2K mice, suggesting that they were less fearful and more exploratory. No sex 
differences for exploration were found but male mice defecated more than 
females in the elevated plus maze. In the open field there were no significant 
strain or sex differences in measures of exploration or fear. There were no strain 
differences in the investigation of a novel object placed into the open field, but 
males investigated the novel object more than females. 
Fredriksson and Archer, (1994) [50] scrutinized and reported Two experiments 
were performed to study the parametric effects of long-term administration of the 
neurotoxin, 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP), as a functional 
model of Parkinsonism in mice. DA depletions were severe at all five test 
intervals. These results offer functional and neurochemical evidence that MPTP 
treatment produces permanent damage to the nigrostriatal motor system in mice. 
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AIM AND OBJECTIVE 
Parkinson‘s disease (PD) is a progressive neurodegenerative 
disorder that affects small regions in the brain that control movement, posture 
and balance. It is a complex disease that has many different symptoms, so that 
not everyone with the condition suffers from the same problems. There are up to 
10 million people in the world (i.e., approximately 0.3% of the world population) 
and 1% of those above 60 years be affected with PD.  
The pathology of PD involves the depletion of dopamine, 
degeneration of dopaminergic neurons in the nigro striatum, etc. Usually the 
inhibitory dopaminergic system and excitatory cholinergic system strike a 
balance in maintain the posture locomotion, motor reflexes, etc. In PD, the 
balance is affected due to the dopaminergic nerve degeneration and cholinergic 
nerves get upper hand leading to symptoms of PD.   
Majority of population still have limited access or no access to 
modern medicines and rely on traditional ways of treatment. India being a 
country with rich floral diversity houses around 45,000 plant species. Use of 
herbal drugs for treating ailments is followed in Ayurveda, Yoga, Siddha, Unani, 
Homeopathy and Naturopathy forms of alternative medicines. Herbal medicines 
are now in great demand among the population in developing countries because 
they are inexpensive, better cultural acceptability, better compatibility with human 
body and minimal side effects. 
Currently the PD is treated with the drugs those increase the 
dopaminergic activity like, precursors of dopamine (levodopa), drugs that inhibit 
dopamine metabolism (MAO inhibitors and COMT inhibitors), drugs that release 
dopamine (Amantadine), dopamine receptor agonist (Ergot derived: 
Bromocriptine, Non ergot: Pramipexole) and drugs those that suppress the 
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cholinergic activity (Atropine and its substitutes). Our current medication have 
been shown to improve symptoms, by restoring more normal chemical balance in 
the brain between the dopaminergic and cholinergic nerves, thereby reducing the 
symptoms of PD. But, the altered pathological changes are not improved and 
also oxidative metabolism of some of the agents actually accelerates further 
damage, leading to irreversible and untreatable symptoms severely affecting the 
quality of life of the patient and to death. 
Alternative and traditional medicine is becoming an increasingly 
important therapeutic option in various morbidities including neurodegenerative 
disorders.  In this line, WHO has recommended the evaluation of effectiveness of 
plants in condition where we lack a safer modern drug. Thus, a proper scientific 
evaluation and screening of plants by pharmacological and chemical 
investigations for the discovery of potential anti-parkinsonism agents is need of 
the hour with possible outcomes to prevent, delay, reduce and/or treat 
neurodegeneration. 
Based on this background, the present research work on the 
validation of medicinal plant Cymbopogon flexuosus was carried out. The 
quintessential aim is to find out the effect of Cymbopogon flexuosus (lemongrass 
oil) against rotenone-induced Parkinsonism in rats. Objectives of the present 
study include the extraction of lemon grass oil from the plant Cymbopogon 
flexuosus leaves, qualitative evaluation of phytoconstituents present, testing for 
its toxicity, optimizing the rotenone-induced model for Parkinsonism in rats and 
studying the effect of the extracted oil against rotenone-induced Parkinsonism in 
rats.  
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MATERIALS AND METHODS 
Cymbopogon flexuosus (Family: Poaceae), the plant used in the study, is 
available all over India, Sri Lanka, Burma and Thailand [18]. The plant has been 
used in traditional system of medicine for the treatment of fever, stimulant and 
used as a flavouring agent, carminative and perfumery [19]. The fresh leaves of 
this plant was used in this study. In this part of work the collection and 
authentication of the plant material, extraction, phytochemical screening and 
acute toxicity studies are described. 
COLLECTION & AUTHENTICATION OF PLANT MATERIAL AND 
EXTRACTION & PHYTOCHEMICAL SCREENING OF OIL 
Collection 
Cymbopogon flexuosus (lemongrass) used in this work was collected in 
bulk from Ootacamund, Tamil Nadu, India during January 2017. A herbarium was 
prepared featuring the salient features of the plants and submitted for 
authentication. The plant was authenticated by Dr. C. Murugan, Scientist D & 
Head of Office, Botanical Survey of India, Tamil Nadu Agricultural University 
Campus, Coimbatore viz., authentication letter bearing No: 2948 dated 
23.01.2017  
Drugs & Chemicals 
Anhydrous sodium sulphate, n-hexane purchased from HiMedia, Mumbai. 
All the other chemicals and reagents used were commercially purchased and 
were of analytical grade.  
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Extraction of oil [36] 
The lemongrass oil was extracted by hydro-distillation method. About 
900g of fresh lemongrass was weighed and placed in a 500ml round bottom flask 
containing 250 ml of water and was subjected to hydro-distillation for 12 hours. 
 
Fig.No.7: Diagramatic representation of distillation setup used for 
extraction of lemon grass oil from Cymbopogon flexuosus leaves 
 
The distillate was saturated with sodium chloride and added with n-hexane and 
shaken for half an hour. Then, the n-hexane layer and hydro layer were 
separated by separating funnel. Anhydrous sodium sulphate was added to 
dehydrate the n- hexane layer and the dehydrated layer was further dried at  
40°C, during which the oil separates out. The extracted lemon grass oil obtained 
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from Cymbopogon flexuosus leaves (LOCFL) was stored in air-tight container 
and kept in room temperature in dark until further studies.  
Phytochemical Screening of LOCFL 
Following chemical tests were performed for the presence of phytochemical 
constituents in LOCFL as per the procedures explained by Trease and Evans [51]. 
A. Test for Carbohydrates 
Molisch’s test: 
LOCFL was mixed with few drops of Molisch reagent (alpha naphthol) and 
concentrated sulphuric acid was added from sides of test tube. A purple coloured 
ring formation at junction indicates presence of carbohydrates. 
Fehling’s test: 
Equal volume of Fehling‘s A and Fehling‘s B were mixed (1 ml each) and 
2 ml of LOCFL was added followed by boiling for 5-10 minutes on water bath 
(Fehling‘s A solution composed of 0.5% of copper sulphate and Fehling‘s B 
solution composed of sodium potassium tartrate).The formation of reddish brown 
coloured precipitate (due to formation of cuprous oxide) indicates presence of 
reducing sugar. 
Benedict’s test: 
It used for test reducing sugars and the Benedict‘s reagent composed 
mainly of copper sulphate and sodium hydroxide. To about 4ml of LOCFL, 1ml of 
Benedict‘s solution was added and heated almost to boiling. Green, yellow, 
orange, red or brown colour formation occurs in order of increasing concentration 
of simple sugar in the test solution (due to formation of cuprous oxide).  
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B. Test for proteins and amino acids 
Biuret test: 
To LOCFL in hot water, few drops of Biuret reagent (potassium hydroxide, 
copper sulphate and sodium potassium tartrate) was added, which turns blue 
reagent to violet. Usually in laboratory, it can also be done by adding few drops 
of 0.5% copper sulphate solution to the extract. 
Millon’s test: 
Millon‘s test is usually positive for any compound containing a phenolic 
hydroxyl group. Millon reagent is a solution of mercuric and mercurous ions in 
nitric and nitrous acids. 1ml of LOCFL was taken in a test tube and few drops of 
Millon‘s reagent were added. The formation of white precipitate, which turns red 
after heating for 5 minutes on water bath indicates positive reaction (due to 
formation of a mercury salt of nitrated amino acid). 
Ninhydrin test: 
This test is mainly used to detect the presence of alpha-amino acids and 
proteins containing free amino groups. LOCFL when heated with Ninhydrin 
molecules, gives characterstic deep blue or pale yellow colour due to formation 
of comple between two ninhydrin molecules and the nitrogen of free amino acid. 
C. Test for glycosides 
Baljet test: 
LOCFL when mixed with sodium picrate solution forms yellow to orange 
colour in presence of aglycones or glycosides.  
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Legal test: 
To LOCFL equal volume of water and 0.5 ml of strong lead acetate 
solution was added, mixed and filtered. Filtrate was extracted with equal volume 
of chloroform and the chloroform extract was evaporated to dryness. The residue 
was dissolved in 2 ml of pyridine and sodium nitroprusside 2 ml was added 
followed by addition of sodium hydroxide solution to make alkaline. Formation of 
pink colour indicates the presence of glycosides or aglycone moiety. 
D. Test for saponins 
Foam test: 
To 1ml LOCFL, 10-20 ml of water was added; shaken for few minutes, 
formation of frothing which persists for 60-120 seconds indicates the presence of 
saponins.  
E. Test for steroids and triterpenoids 
Libermann Burchard test: 
LOCFL was evaporated to dryness and extracted with chloroform, add few 
drops of acetic anhydride followed by concentrated sulphuric acid from side wall 
of test tube to the chloroform extract. Formation of violet to blue coloured ring at 
the junction of two liquids, indicate the presence of steroid moiety.  
Salkovaski test: 
LOCFL was evaporated to dryness and extracted with chloroform, add 
concentrated hydrochloric acid from sidewall of test tube to the chloroform 
extract. Formation of yellow coloured ring at the junction of two liquids, which 
turns red after 2 minutes, indicates the presence of steroid moiety. 
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F. Test for flavonoids 
Ammonia test: 
Filter paper dipped in LOCFL was exposed to ammonia vapour. Formation 
of yellow spot on filter paper indicates the presence of this type of glycosides. 
Concentrated sulphuric acid test: 
LOCFL was treated with concentrated sulphuric acid to give a yellow 
colour. 
Aluminium chloride test: 
LOCFL was treated with 1% aluminium chloride. Formation of yellow 
colour indicates the presence of flavonoids. 
G. Test for alkaloids and/or nitrogenous bases 
Dragendorff’s test: 
LOCFL was treated with Dragendorff‘s reagent (potassium bismuth 
iodide). The formation of orange red colour or precipitate is an indication of the 
presence of alkaloids. 
Mayer’s test: 
LOCFL was treated with few drops of Mayer‘s reagent (potassium 
mercuric iodide). The formation of a turbid or creamy-white precipitant is an 
indication of presence of alkaloids. 
Hager’s test: 
LOCFL was treated with few drops of Hager‘s reagent (Saturated aqueous 
solution of picric acid). The formation of crystalline yellow precipitate is an 
indication of the presence of alkaloids. 
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Wagner’s test: 
LOCFL was treated with few drops of Wagner‘s reagent (dilute iodine 
solution). The formation of reddish brown precipitate is an indication of the 
presence of alkaloids. 
Tannic acid test: 
Few drops of tannic acid solution added to LOCFL. The formation of buff 
coloured precipitate is an indication of the presence of alkaloids. 
H. Test for tannins and phenolics 
LOCFL was treated with 5% ferric chloride to give a brown colour. 
 
ACUTE TOXICITY AND IN VIVO STUDIES 
EXPERIMENTAL ANIMALS 
Healthy adult male Sprague Dawley rats weighing 220g±20% were 
procured from Kerala Veterinary and Animal Science University, Thrissur. The 
study protocol was approved by the Institutional Animal Ethical Committee 
(COPSRIPMS/IAEC/PG/P‘COLOGY/03/2017-2018) and all procedures were 
performed in accordance with the recommendations for the proper care and use 
of laboratory animals.  
Housing and feeding conditions 
The animals were kept in cages under ambient temperature (22 ± 3°C) 
with 12 h light/dark cycle. They were fed with standard rat laboratory diet and 
drinking water ad libitum. 
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Drugs & Chemicals 
Anhydrous sodium sulphate, bovine serum albumin, tri-chloro acetic acid, 
thiobarbituric acid and DTNB (Ellman‘s reagent) were purchased from HiMedia,  
Mumbai; glutathione, sodium pyrophosphate, rotenone was purchased from 
Sigma Aldrich, United states; Levodopa (Syndopa) were purchased from Sri 
Ramakrishna Hospital Pharmacy, Coimbatore. Alkaline phosphatase (ALP), 
Aspartate transaminase (AST), Alanine transaminase (ALT), Lactate 
dehydrogenase (LDH), obtained from Agappe Diagnostics, Cochin, India. All the 
other chemicals and reagents used were commercially purchased and were of 
analytical grade.  
Instruments / Equipment 
Semi auto-analyzer (Agappe Diagnostics Ltd, Mumbai), centrifuge (Remi 
Instruments Ltd., Kolkata) UV- Visible Spectrophotometer (JASCO V-630 
spectrophotometer), pH meter, Digital balance (CAS-CBL), open field apparatus, 
rearing chamber (Ananya Enterprises, Coimbatore), elevated plus maze and 
wooden blocks were assembled by in-house carpenters.  Sand-paper was 
purchased locally.   
Acute Toxicity Study of LOCFL 
Acute oral toxicity testing was carried out in accordance with the OECD guideline 
420 Acute Oral Toxicity – Fixed Dose Procedure method [52].  
Procedure  
The acute toxicity study was done by two steps - Sighting study and Main 
study.  
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The purpose of the sighting study is to allow selection of the appropriate 
starting dose for the main study.  
 Sighting study was conducted using one animal and main study using five 
animals, in which one animal is taken from the sighting study. Healthy adult 
female (generally slightly more sensitive than male) Sprague Dawley rats 
weighing between 220±20%g body weight were procured and kept in cages 
under ambient temperature (22±3°C) with 12 h light/dark cycle. The animals were 
randomly selected, marked and kept in their cages for 5 days prior to dosing for 
acclimatization to laboratory conditions. An animal was fasted over-night but 
water provided ad libitum and received a single dose (2000mg/kg, body weight, 
p.o.) of lemongrass oil emulsion (prepared by adding LOCFL with water 
containing 0.5%w/v acacia gum as emulsifying agent). After the administration of 
the extract, food was withheld for further 3-4h.  
Animals were observed individually at least once during the first 30 min 
after dosing, periodically during the first 24h (with special attention during the first 
4 h) and daily thereafter for a period of 14 days. Once daily cage side 
observations included changes in skin and fur, eyes and mucous membrane 
(nasal), and also respiratory rate, circulatory (heart rate and blood pressure), 
autonomic(salivation, lacrimation, perspiration, piloerection, urinary incontinence 
and defecation) and central nervous system (drowsiness, gait, tremors and 
convulsions) changes. 
 If the animal dosed with 2000mg/kg b.w. during the sighting study survives 
and remains so without any toxic manifestations then the same dose is selected 
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for the main study. The main study was done in 4 animals other than that taken 
for the sighting study (a total of 5 animals). The procedure of the main study is 
similar to that of the sighting study. 
IN VIVO ACTIVITY 
Selection of dose of the oil emulsion 
LD50 was determined as per OECD guidelines for fixing the dose for 
biological evaluation. The LD50 of the LOCFL falls under category 5, with no 
death and no signs of acute toxicity at doses of 2000 mg/kg as per the Globally 
Harmonized System (GHS) of classifying toxic substances, can be considered to 
be 2000mg/kg b.w. Hence one-tenth of LD50, i.e., 200 mg/kg b.w. is fixed as the 
maximum dose for testing the biological activity. Two dose levels of 100 and 200 
mg/kg b.w. are used in the biological evaluation of LOCFL to check any dose-
dependent variation in biological response. 
Experimental Design 
Male Sprague Dawley rats weighing 220±20%g b.w. were divided into six 
groups, each consisting of six rats. The animals were numbered in each group 
using permanent marker in the base of their tails. The total treatment period was 
21 days. Prior to the treatment the animals were trained for behavioural 
procedures using open field apparatus, rotarod, elevated plus maze and rearing 
chamber for three days. The various groups and treatments provided are 
described in the following table [1, 33]:  
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Table No.1: Group and Treatment  
Group No Group Name Treatment 
I Vehicle Control Coconut oil (1 ml/kg/day; p.o.) 
II Negative Control Rotenone (2.5 mg/kg/day in coconut oil; i.p.) 
III 
Positive Control 
(Levodopa group) 
Rotenone (2.5 mg/kg/day in coconut oil; i.p.) 
+ Levodopa (10 mg/kg/day in 0.5%w/v 
carboxy methyl cellulose suspension; p.o.) 
IV 
Low Dose Test 
Group 
Rotenone (2.5 mg/kg/day in coconut oil; i.p.) 
+ LOCFL (100 mg/kg/day emulsion; p.o.) 
V 
High Dose Test 
Group 
Rotenone (2.5 mg/kg/day in coconut oil; i.p.) 
+ LOCFL (200 mg/kg/day emulsion; p.o.) 
VI 
LOCFL Alone 
Group 
LOCFL (200 mg/kg/day emulsion; p.o.) 
 
The treatment period is for 21 days. During the treatment period the body 
weight was checked every day prior to treatment and behavioural parameters 
were recorded every week. Twenty-four hours after the last administration the 
animals were bled under ether anaesthesia, euthansied by cervical dislocation 
and brains dissected out for further studies.   
BEHAVIOURAL PARAMETERS 
1. Open field test 
Principle: 
 Parkinson‘s disease is a syndrome of varied etiology and its important 
features are bradykinesia, muscular rigidity, postural instability, loss of 
associated movements and tremors [53]. It is a movement disorder which cause 
decreased locomotor activity and it is measured by open field apparatus or by 
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actophotometer. The open field is used for measuring anxiety and exploration as 
well as locomotion as it has large center arena. 
Apparatus: 
The open field apparatus constructed of clear plexiglass and measured 
72×72cm with 36cm height, so rat could be visible through the walls. The floor of 
the chamber is divided into sixteen 18×18cm squares. A central square 
(18×18cm) was drawn in the middle of the open field.  
Procedure: 
 Rats were carried to the test room in their home cages and were handled 
by the base of their tails at all times. Rats were placed into the center or one of 
the four corners of the open field and allowed to explore the apparatus for 5 
minutes.After the 5 minute test, rat were returned to their home cages and the 
open field was cleaned with 70% ethyl alcohol and permitted to dry between 
tests. To assess the process of habituation to the novelty of the arena, rats were 
exposed to the apparatus for 5 minutes on 2 consecutive days [48].  
Fig. No. 8: Picture of open field apparatus used in the study 
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Scores:  
1. Line crossing 
Frequency with which the rat crossed one of the grid lines with all four 
paws. 
2. Central square entries 
Frequency with which the rat crossed one of the red lines with all four paws 
into the central square.  
3. Central square duration 
Duration of time the rat spent in the central square 
4. Stretch attend posture 
Frequency with which, the rat demonstrated forward elongation of the head 
& shoulders followed by retraction to its original position. 
2. Rotarod test 
Principle  
 The Rotarod test is widely used to evaluate the motor coordination of 
rodents and is especially sensitive in detecting cerebellar dysfunction. The 
modified Rotarod test would be useful for evaluation of dopamine involvement in 
the acquisition of motor skill learning [54].  
Instrument: 
The apparatus consist of a horizontal wooden rod or metal rod coated with 
rubber with 3 cm diameter attached to a motor with the speed adjusted to 20 
rotations per minute. The rod is 75 cm in length and is divided into six sections by 
plastic discs, thereby allowing the simultaneous testing of six rats. The rod is in a 
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height of about 50 cm above the table top in order to discourage the animals 
from jumping off the roller [55].  
Procedure 
 Turn on the Rotarod. Select an appropriate speed (20-25 rpm is ideal). 
Place the animal one by one on the rotating rod.  
Fig.No.9: Picture of Rotarod apparatus used in the study 
 
Note down the ‗fall off time‘ when the rat falls from the rotating rod. A cut 
off time was 180 seconds at which the animal is taken off the rotating rod if it has 
not fallen by then. 
3. Elevated plus maze 
Principle  
This degeneration of dopaminergic nigrostriatal system is largely 
responsible for the classical motor signs, including: resting tremor, muscle 
rigidity, and Bradykinesia. Furthermore, non-motor symptoms (NMS) are also 
becoming increasingly recognized as relevant symptoms in PD patients. NMS 
can include emotional and cognitive deficits, sleep disorders, and autonomic, 
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gastrointestinal, and sensory dysfunction.  Anxiety may also be comorbidity for 
PD patients, affecting up to 40% of individuals, sometimes in association with 
depression. The elevated plus maze was used to assess for anxious-like 
behavior [56].  
Apparatus: 
The plus-maze consists of two open arms, 50×10×40 cm and two closed 
arms, 50×10×40 cm, with an open roof, arranged so that the two open arms are 
opposite to each other. The maze is elevated to the height of 50cm.  
Procedure  
The rats are handled by the investigator on alternative days to reduce 
stress. Thirty minutes after i.p. administration of test/standard, the rat is placed in 
the center of the maze, facing one of the enclosed arms.  
Fig.No.10: Picture of Elevated plus maze apparatus used in the study 
 
The rats are housed in pairs for 10 days prior to testing in the apparatus. 
During the 5 minute test period the following measures are taken: 
1. The number of entries into the open and enclosed arms 
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2. Time spent in the open arm and enclosed arm 
3. The first preference of the animal to the open arm or closed arm 
The procedure is conducted preferably in a sound attenuated room, with 
observations made from an adjacent room. 
4. Catalepsy test 
Principle  
Neuroleptic or neurotoxins induced catalepsy in rats is used to 
evaluate the drugs for their antiparkinsonism effects. This exerts multiple events 
on dopeminergic signaling and produce DA related behavioural changes and 
catalepsy [57]. This activity used to assess extrapyramidal side effects such as, 
akinesia, rigidity and tremors, are called Parkinson‘s – like because Parkinson‘s 
disease the major clinical symptoms include difficulty to move and change 
posture (akinesia and rigidity) and tremors. 
 Neuroleptic-induced catalepsy has long been used as an animal model for 
screening drugs for Parkinsonism. It induces a behavioral state known as 
catalepsy in which the animals are unable to correct externally imposed  
postures [58].  
Procedure  
Two wooden blocks one being 3 cm high and the other 9 cm high.  
Animals were treated with drug/standard/inducing agent and observed 
severity of catatonic response as follows: 
Stage I: Rat moves normally when placed on the table, score – 0  
Stage II: Rat moves only when touched or pushed, score – 0.5  
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Fig.No.11: Picture of Wooden blocks used in the study 
       3rd stage of catatonia                         4th stage of catatonia  
            
Stage III: Rats placed on the table with front paws set alternately on a 3 
cm high block fails to correct the posture in 10 seconds, score – 0.5 for each paw 
with a total of 1 for this stage 
Stage IV: Rat fails to remove when the front paws are placed alternately 
on a 9 cm high block, score – 1 for each paw with a total score of 2 for this stage. 
5. Rearing behavior 
Principle  
The rearing test is used to assess the exploratory behavior when they rear 
and contact the wall of the cylinder with their forepaws. The number of wall 
contacts made using one or both the forelimbs is recorded [45].  
Apparatus: 
The rearing chamber was made up of clear plexiglass acrylic sheets with 
the height of 30 cm and 20 cm in diameter. The chamber is height enough to 
prevent rats from jumping out, and wide enough to allow a small (1cm) gap 
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between the base of the tail and the cylinder wall when the rat is on surface of 
the chamber with all forepaws.  
Procedure  
When placed in a clear cylinder, rats will engage in exploratory behavior, 
including rearing. During rearing behavior, the forelimbs will contact the wall of 
the rearing chamber. For this test, the rat was placed in a clear plexiglass 
chamber for 5 min. 
To be classified as a rear, the animal had to raise forelimbs above 
shoulder level and make contact with the cylinder wall with either one or both 
forelimbs.  
Fig.No.12: Picture of Rearing chamber used in the study 
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Removal of both forelimbs from the cylinder wall and contact with the table 
surface was required before another rear was scored. 
This test has been successfully used previously to assess behavioral 
deficits in the rats receiving subcutaneous or intravenous rotenone [43].  
6. Postural instability test 
Principle  
Postural instability is a hallmark feature of PD. Rotenone produces 
bilateral symptoms [43]. This is a new test that is a refinement of an earlier test 
variously referred to as the stepping test, adjusting-steps test, or bracing test 
which, in contrast to the present postural instability test, measured number of 
steps taken across a set distance of displacement also measured subsequent 
multiple steps, as well as sideways stepping.  
Procedure 
Rats were held almost vertically upside-down (in a ―wheelbarrow‖- like 
position) over a sandpaper-covered surface alongside a ruler, by a tester who 
was blind to the experimental condition of the rats.  
This rough surface material induced stepping, rather than dragging or 
bracing, in response to imposed weight shifts. Viewed from above, the tip of the 
rat's nose was aligned with the zero line of the ruler, and one forelimb was gently 
restrained against the animal's torso by the experimenter while the animal was 
moved forward over the single planted forelimb until making a ―catch-up‖ step to 
regain its center of gravity [45].  
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Fig.No.13: Postural Instability study by using Sand-paper    
   
Figure 13 (a)                                         Figure 13 (b) 
Figure 1 – The angle at which the rat was held 
Figure 2 – A rat made a catch-up step with the right limb after 9.5 cm of 
displacement 
The new position of the nose tip indicated the displacement of the body 
needed to trigger a catch-up step in the unrestrained supporting forelimb.  
We examined each forelimb independently while slowly shifting the center 
of gravity during weight support. We performed three trials on each forelimb on a 
given day of testing. 
DISSECTION AND BLOOD COLLECTION 
Twenty-four hours after the last administration the blood was collected by 
retro orbital puncture from the inner canthus of the eye under mild ether 
anaesthesia using capillary tubes in fresh pro-coagulation tubes and serum was 
separated by centrifugation and used for further studies.  
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Fig.No.14: Collection of blood by Retro orbital puncture 
                       
 
Serum parameters like,   
1. Alkaline phosphatase (ALP) 
2. Aspartate transaminase (AST) 
3. Alanine transaminase (ALT)  
4. Lactate dehydrogenase (LDH)   
 
1. Alkaline phosphatase 
Principle 
Kinetic determination of ALP according to the following reaction 
Para-nitrophenyl phosphate + H2O 
ALP
    p-nitrophenol + Inorganic phosphate 
ALP is widely distributed throughout the body, but clinically important one for 
diagnostic reasons are in bone, liver, placenta and intestine.  
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Reagent preparation  
Mix four volumes of reagent 1 (R1), which contains diethanolamine buffer 
(pH 10.2) 125 mmol/L, magnesium chloride 0.625 mmol/L with one volume of 
reagent 2 (R2) contains P-Nitro phenyl phosphate 50 mmol/L. This working 
reagent is stable for 30 days at 2-8°C. 
 
Procedure  
To 20 µl of sample, 1 ml of working reagent was added. Mix and incubate 
at 37°C for one minute. Measure the change in absorbance per minute during 3 
minutes at 405 nm.  
 
2. Aspartate transaminase 
Principle  
Kinetic determination of aspartate aminotransferase (AST) based upon the 
following reaction. 
L-Aspartate + alpha-ketoglutarate    
AST
     Oxaloacetate + L-Glutamate 
 
Oxaloacetate + NADH + H
+
       L-Malate + NAD
+ 
MDH: Malate dehydrogenase 
Reagent preparation 
Mix four volume of reagent 1 (R1) contains tris buffer (pH 7.8) 88 mmol/L, 
L-aspartate 260 mmol/L, LDH>1500 U/L, MDH>900 U/L with one volume of 
MDH 
 
66 
reagent 2 (R2) contains alpha-ketoglutarate 12 mmol/L, NADH-0.24 mmol/L. This 
working reagent is stable for 30 days at 2-8°C. 
 
Procedure  
To 100 µl of sample, 1 ml of working reagent was added. Mix and incubate at 
37°C for one minute. Measure the change in absorbance per minute during 3 
minutes at 340nm. 
3. Alanine transaminase 
Principle  
Kinetic determination of Alanine transaminase (ALT) according to the 
following reaction.  
L-Alanine + alpha-ketoglutarate
 
------> Pyruvate + L-Glutamate 
Pyruvate + NADH + H
+        
-------> L-Lactate + NAD
+
 
LDH- Lactate dehydrogenase 
 
Reagent preparation 
Mix four volume of reagent 1 (R1) contains tris buffer (pH 7.5) 110 
mmol/L, L-alanine 600 mmol/L, LDH>1500 U/L, with one volume of reagent 2 
(R2) contains alpha-ketoglutarate 16 mmol/L, NADH-0.24 mmol/L. This working 
reagent is stable for 30 days at 2-8°C. 
 
 
 
MDH 
LDH 
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Procedure  
To 100 µl of sample, 1 ml of working reagent was added. Mix and incubate at 
37°C for one minute. Measure the change in absorbance per minute during 3 
minutes at 340nm. 
 
4. Lactate dehydrogenase 
Principle  
Kinetic determination of lactate dehydrogenase according to the following 
reaction.  
Pyruvate + NADH + H
+        
-------> L-Lactate + NAD
+
 
Reagent preparation 
Mix four volume of reagent 1 (R1) contains tris buffer (pH 7.4) 80 mmol/L, 
pyruvate 1.6 mmol/L, sodium chloride 200 mmol/L with one volume of reagent 2 
(R2) contains NADH- 240 mmol/L. This working reagent is stable for 21 days at 
2-8°C. 
Procedure  
To 10 µl of sample, 1 ml of working reagent was added. Mix and incubate 
at 37°C for one minute. Measure the change in absorbance per minute during 3 
minutes at 340nm. 
These parameters were determined using standard kits obtained from 
Agappe Diagnostics, Cochin, India using a Semi Auto-analyser (Mispa Viva, 
Mumbai, India).    
 
LDH 
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Isolation of brain  
Decapitate the animal with a pair of sharp, sturdy scissors or a single-
edged razor blade. This is most easily done by first cutting through the skin and 
muscles around the circumference of the neck and then cutting the head off at 
the base of the skull, just behind the ears. 
Cut through the skin on the top of the head, from the back of the head 
forward to between the eyes. Remove any muscle tissue that may still be 
attached to the base of the skull.  
Locate the foramen magnum, a large opening at the back of the head 
where the spinal column enters the skull. Place one tip of the forceps into the 
foramen magnum, and crack and pull away the bone and tissue on either side of 
the opening. Hold the forceps horizontally and slightly angled downward.  
Place the tips of the forceps in the eye sockets, and crack the piece of 
skull that lies between them. 
Using the forceps, carefully begin to remove the skull. Start at the top of 
the foramen magnum and chip away the bone, up over the cerebellum and then 
forward toward the eyes. Continue removing bone (always holding the forceps 
horizontally) until the brain is exposed on three sides. 
Once all of the bone has been removed from around the brain, hold the 
head upside down. At this point, it should be possible to carefully pry the brain 
away from the base of the skull with a flat metal spatula. The brain will still be 
attached to the skull by the optic and trigeminal nerves.  
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Sever these nerves with the edge of the spatula, and let the brain drop 
into a glass container, Label the cap with the rat‘s number or other  
identification [59]. 
Preparation of tissue homogenates 
The brain was removed and washed immediately with ice-cold saline to 
remove blood. A 10% w/v brain homogenate was prepared in ice-cold potassium 
phosphate buffer (100mM, pH 7.4) followed by centrifugation at 5000g for 10 
min. the resulting supernatant was used for the estimation of biochemical 
parameters.  
 
A. Biochemical parameters 
1. Estimation of total protein content 
2. Estimation of malondialdehyde (MDA) 
B. Determination of enzymatic antioxidants 
3. Assay of catalase 
4. Estimation of glutathione peroxidase (GPx) 
5. Assay of superoxide dismutase (SOD) 
6. Estimation of glutathione reductase (GSSH) 
C. Determination of non-enzymatic antioxidants 
7. Estimation of reduced glutathione (GSH) 
 
 
 
 
70 
A. Biochemical parameters 
1. Estimation of total protein content 
To 0.1ml of brain homogenate, 4.0 ml of alkaline copper solution was 
added and allowed to stand for 10 min [60]. Then, 0.4 ml of phenol reagent was 
added very rapidly and mixed quickly and incubated in room temperature for 30 
min for colour development. Reading was taken against blank prepared with 
distilled water at 610 nm in UV-visible spectrophotometer. The protein content 
was calculated from standard curve prepared with bovine serum albumin and 
results were expressed as µg/mg brain tissue. 
2. Estimation of malondialdehyde (MDA) 
One ml of the homogenate was combined with 2 ml of TCA-TBA-HCl reagent 
(15% trichloro acetic acid (TCA) and 0.375% thiobarbituric acid (TBA) in 0.25 N 
HCl) and boiled for 15 min. precipitate was removed after cooling by 
centrifugation at 1000g for 10 min and absorbance of the sample was read at 
535 nm against a blank without tissue homogenate. The levels of MDA were 
calculated using extinction coefficient calculation [61]. The values are expressed 
as nmoles/min/mg brain tissue. 
B. Determination of enzymatic antioxidants 
3. Assay of catalase 
The reaction mixture contained 2.0 ml of homogenate and 1.0 ml of 30 
mM hydrogen peroxide (in 50 mM phosphate buffer, pH 7.0). a system devoid of 
the substrate (hydrogen peroxide) served as a control. Reaction was started by 
the addition of the substrate and decrease in absorbance mentioned at 240 nm 
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for 30 seconds at 25°C. the difference in absorbance per unit time was 
expressed as the activity and three parallel experiments were conducted. One 
unit is defined as the amount of enzyme required to decompose 1.0 M of 
hydrogen peroxide per minute at pH 7.0 and 25°C [62]. 
 
4. Estimation of glutathione peroxidase (GPx) 
The reaction mixture consists of 0.2 ml of 0.4 M Tris buffer, 0.1 ml of 1.0 
mM sodium azide, 0.1 ml of 0.042% hydrogen peroxide, 0.2 ml of 200 mM 
glutathione and 0.2 ml of brain tissue homogenate supernatant incubated at 37°C 
for 10 min. The reaction was arrested by the addition 0.1 ml of 10% TCA and the 
absorbance was taken at 340 nm [63]. Activity was expressed as nmoles/min/mg 
brain protein. 
 
5. Assay of superoxide dismutase (SOD) 
The assay mixture contained 1.2 ml of sodium pyrophosphate buffer 
(0.052 M, pH 8.3), 0.1 ml of 186 µM Phenazonium methosulphate (PMS), 0.3 ml 
of 300 µM nitro blue tetrazolium chloride (NBT), 0.2 ml of 780 µM NADH, 1.0 ml 
of homogenate and distilled water to a final volume of 3.0 ml. reaction was 
started by the addition of NADH and incubated at 30°C for 1 min. the reaction 
was stoped by the addition of 1.0 ml of glacial acetic acid and the mixture was 
stirred vigorously. 4.0 ml of n-butanol was added to the mixture and shaken well. 
The mixture was allowed to stand for 10 min, centrifuged, the butanol layer was 
taken out and absorbance was measured at 560 nm against a butanol blank [64]. 
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A system devoid of enzyme served as the control and three parallel experiments 
were conducted.  
6. Estimation of glutathione reductase (GSSH) 
The enzyme activity was determined spectrophotometrically by the 
decrease in absorbance of NADPH at 340 nm. The reaction mixture contained 
2.1 ml of 0.25 mM potassium phosphate buffer pH 7.6, 0.1 ml of 0.001 M 
NADPH, 0.2 ml of 0.0165 M oxidized glutathione and 0.1 ml of bovine serum 
albumin (10 mg/ml). The reaction was started by the addition of 0.02 ml of brain 
tissue homogenate with mixing and the decrease in absorbance at 340 nm was 
measured for 3 min against a blank [65]. Glutathione reductase activity was 
expressed as nmoles/min/mg brain protein at 30°C.  
 
C. Determination of non-enzymatic antioxidants 
7. Estimation of reduced glutathione (GSH) 
Brain was homogenized in 10% w/v cold 20mM EDTA solution on ice. 
After deproteinization with 5% TCA, an aliquot of the supernatant was allowed to 
react with 150 µM DTNB. The product was detected and quantified 
spectrophotometrically at 416 nm [66]. Pure GSH was used as standard for 
establishing the calibration curve and three parallel experiments were conducted. 
Histopathological Studies 
Brain tissues isolated from rats were used for histopathological studies.  
Preparation of the tissue for Histology 
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Fixation of solution: Picric acid (Saturated solution) – 75 ml; formaldehyde 40% - 
25ml and glacial acetic acid – 5 ml [67]  
Procedure: After sacrificing the rat by cervical dislocation, brain tissues were 
collected, washed in normal saline and fixed using the above mentioned fixative 
for 24 h and the tissues were sent for histopathological studies. 
STATISTICAL ANALYSIS 
Results were expressed as mean ± SEM of six animals in each group. 
The groups were compared using Student‘s Paired ‗t‘ test and One-way Analysis 
of Variance (ANOVA) with Tukey‘s test when and where appropriate. P values 
<0.05 were considered as significant. 
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RESULTS 
Percentage yield of the LOCFL 
The lemon grass oil was extracted from Cymbopogon flexuosus leaves 
using hydro-distillation process and the percentage yield of the LOCFL was 
found to be 1.10% w/w. 
Phytochemical screening  
The phytochemical screening of the LOCFL confirmed the presence of 
alkaloids, flavonoids, saponins, carbohydrates, amino acids and glycosides. The 
results were tabulated in Table 2. 
Acute toxicity studies 
 LD50 was determined as per OECD guidelines for fixing the dose for 
biological evaluation. The LD50 of the LOCFL falls under category 5, with no 
death and no signs of acute toxicity at doses of 2000 mg/kg as per the Globally 
Harmonized System (GHS) of classifying toxic substances can be considered to 
be 2000mg/kg b.w.  The observations made were tabulated in Table No. 3. 
Hence one-tenth of LD50, i.e., 200 mg/kg b.w. is fixed as the maximum dose for 
testing for biological activity. Two dose levels, i.e., 100 mg/kg and 200 mg/kg. 
were used in the biological evaluation of LOCFL to check if there is any dose 
dependent increase in the protection shown by the oil. 
Body weight 
 The initial (0th day) and final (22nd day) body weights of rats used are 
summarized in Table  No. 4. Initial values in control and experimental animals 
were not significantly different. The body weight of normal controls significantly 
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increased by approximately 5.8% over their initial readings after 21 days of 
treatment, whereas there was a significant (p<0.05) decrease in the body weight 
of negative control rats (20.59%). Administration of the LOCFL emulsion, or 
standard (levodopa) in treatment group rats reversed this weight loss and there 
was no significant (p>0.05) difference between initial and final body weight in 
these animals.  
BEHAVIOURAL PARAAMETERS 
1. Open field test 
The negative control rats showed significant decrease (p < 0.01) in number of 
line crosses and number of central square entries and time spent in Central 
Square when compared to vehicle control rats. It showed significant increase (p < 
0.01) in duration of stretch attend posture. The treatment groups showed 
significant increase (p < 0.001) in line crosses, number of central square entries 
and time spent in central square when compared to negative control rats and 
there was a significant decrease (p < 0.001) in the duration of stretch attend 
posture when compared to negative control rats (Table No. 5) 
2. Rotarod test 
Negative control rats showed a significant decrease (p < 0.001) in fall off time 
when compared to vehicle control rats and the percentage decrease in time 
approximately 83.01 % when compared to vehicle control rats. Treatment rats 
with LOCFL and standard, resulted in significant increase (p < 0.001) in fall off 
time when compared to the negative control rats. There is no significant 
difference in percentage decrease in time in these animals. LOCFL alone rats 
 
76 
showed no significant decrease or increase in the fall off time when compared to 
the vehicle control group. The values were comparable with that of standard 
(levodopa) summarized in Table No.  6.  
 
3. Elevated plus maze  
The negative control rats showed significant decrease (p < 0.05) in time spent 
and number of entries to the open arm when compared to the vehicle control 
rats. Treatment rats which showed significant increase (p < 0.05) in time spent 
and number of entries to the open arm when compared to the negative control 
rats. The LOCFL rats showed no significant increase or decrease in the open 
arm entries and time spent in that (Table No. 7).  
4. Catalepsy test 
Negative control rats showed significant decrease (p < 0.01) in catatonic 
response when compared to vehicle control rats. Treatment rats which were 
treated with LOCFL and standard resulted in significant increase (p < 0.001) in 
catatonic response when compared to negative control rats. LOCFL alone rats 
showed no significant decrease or increase in the catatonic response. The 
values were compared between the different groups are summarized in the Table 
No. 8. 
5. Rearing behavior 
In negative control rats, the number of rears decreased significantly (p < 
0.001) when compared to the vehicle control rats. The treatment rats with LOCFL 
and standard, resulted in significant increase (p < 0.001) in the number rears 
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when compared to the negative control rats. LOCFL alone rats showed no 
significant increase or decrease in number of rears when compared with the 
vehicle control rats. The results were summarized in Table No. 9.  
 
6. Postural instability test 
The negative control group showed significant decrease (p < 0.01) in size of 
the adjusting response when compared to vehicle control rats. Treatment rats 
which were treated with LOCFL and standard resulted in significant increase (p < 
0.01) in size of the adjusting response. LOCFL alone rats showed no significant 
increase or decrease in size of the adjusting response when compared to vehicle 
control rats. The values were summarized in Table No. 10.  
Serum parameters 
The activities of serum marker enzymes like ALP, AST, ALT were 
significantly (p < 0.01) increased in negative control group when compared to 
vehicle control group. Treatment groups with LOCFL and levodopa showed 
significant reduction (p < 0.01) in the activities of ALP, AST and ALT when 
compared with negative control rats. The LDH activity were significantly 
increased (p < 0.01) when compared to the vehicle control rats. Rats treated with 
LOCFL and levodopa showed significant decrease (p < 0.001) in the activity 
(Table No. 11). 
Tissue parameters 
There was a significant (p < 0.01) decrease in amount of protein and an 
increase in the concentration of MDA in the brain tissues of negative control rats 
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when compared with vehicle control rats. Reversal to near normal levels was 
seen with treated rats with LOCFL and levodopa (Table No. 12). The levels of 
enzymatic and non-enzymatic antioxidants in the brain tissues of various groups 
of experimental animals are presented in Table No. 13. The activities of 
enzymatic and non-enzymatic antioxidants in the negative control rats were 
significantly lower (p < 0.05) when compared with vehicle control rats.  Rats fed 
with LOCFL and levodopa displayed significant (p < 0.05) increased activities as 
compared to negative control rats. 
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Table No. 2:  Phytochemical screening of LOCFL 
S. NO CHEMICAL TEST LOCFL 
Carbohydrates 
1 A Molisch‘s test + 
2 B Fehling‘s test + 
3 C Benedict‘s test + 
Proteins and Amino acid 
4 A Biuret test - 
5 B Millon‘s test + 
6 C Ninhydrin test + 
Glycosides 
7 A Baljet test + 
8 B Legal test + 
Saponins 
9 A Foam test + 
Steroids and Triterpenoids 
10 a Libermann Burchard test - 
11 B Salkowski test - 
Flavonoids 
12 A Ammonia test + 
13 B Concentrated sulphuric acid test + 
14 C Aluminium chloride test + 
Alkaloids 
15 A Dragendroff‘s reagent + 
16 B Mayer‘s reagent - 
17 C Hager‘s reagent - 
18 D Wagner‘s reagent - 
19 E Tannic acid test - 
Tannins and Phenols 
20 A Ferric chloride test - 
 
LOCFL – Lemongrass oil obtained from Cymbopogon flexuosus leaves + 
denotes presence and – denotes absence of the phytoconstituents.  
 
80 
Table No.3: Acute toxicity studies of LOCFL  
Observation  Score for 
Normal 
animal 
Half 
an 
hour 
Four 
hours 
24 
Hours 
Day 
2 
Day 
4 
Day 
6 
Day 
8 
Day 
10 
Day 
12 
Day 
14 
Lethality  Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
Group Dispersion 0 0 0 0 0 0 0 0 0 0 0 
Locomotor Activity 4 4 4 4 4 4 4 4 4 4 4 
Restlessness 0 0 0 0 0 0 0 0 0 0 0 
Lethargy 0 0 0 0 0 0 0 0 0 0 0 
Writhing 0 0 0 0 0 0 0 0 0 0 0 
Stereotyped behavior 0 0 0 0 0 0 0 0 0 0 0 
Tremors 0 0 0 0 0 0 0 0 0 0 0 
Twitches 0 0 0 0 0 0 0 0 0 0 0 
Convulsions 0 0 0 0 0 0 0 0 0 0 0 
Exophthalmos 0 0 0 0 0 0 0 0 0 0 0 
Respiration 0 0 0 0 0 0 0 0 0 0 0 
Alertness 4 4 4 4 4 4 4 4 4 4 4 
Group startle response 4 4 4 4 4 4 4 4 4 4 4 
NAD  Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
NAD – No abnormalities detected. 
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Table No.3 (Contd.): Acute toxicity studies of LOCFL  
Observation 
Score for 
normal 
animal 
Time of individual observations 
Half an 
hour 
Four 
hours 
24 
Hours 
Day 2 Day 4 Day 6 Day 8 Day 10 Day 12 Day 14 
Loss if Righting reflex 0 0 0 0 0 0 0 0 0 0 0 
Abnormal body carriage 0 0 0 0 0 0 0 0 0 0 0 
Abnormal gait 0 0 0 0 0 0 0 0 0 0 0 
Straub tail 0 0 0 0 0 0 0 0 0 0 0 
Piloerection 0 0 0 0 0 0 0 0 0 0 0 
Touch response 4 4 4 4 4 4 4 4 4 4 4 
Fearfulness 4 4 4 4 4 4 4 4 4 4 4 
Pinna reflex 4 4 4 4 4 4 4 4 4 4 4 
Corneal reflex 4 4 4 4 4 4 4 4 4 4 4 
Catalepsy 0 0 0 0 0 0 0 0 0 0 0 
Passivity 0 0 0 0 0 0 0 0 0 0 0 
Aggressiveness 0 0 0 0 0 0 0 0 0 0 0 
Body tone 4 4 4 4 4 4 4 4 4 4 4 
Grip strength 4 4 4 4 4 4 4 4 4 4 4 
Paralysis 0 0 0 0 0 0 0 0 0 0 0 
Cutaneous blood flow 4 4 4 4 4 4 4 4 4 4 4 
Cyanosis 0 0 0 0 0 0 0 0 0 0 0 
Salivation 0 0 0 0 0 0 0 0 0 0 0 
Lacrimation 0 0 0 0 0 0 0 0 0 0 0 
Ptosis 0 0 0 0 0 0 0 0 0 0 0 
Pupil diameter 4 4 4 4 4 4 4 4 4 4 4 
Pain response 4 4 4 4 4 4 4 4 4 4 4 
Diarrhea 0 0 0 0 0 0 0 0 0 0 0 
Vocalization 0 0 0 0 0 0 0 0 0 0 0 
Increased urination 0 0 0 0 0 0 0 0 0 0 0 
Grooming 4 4 4 4 4 4 4 4 4 4 4 
NAD  Nil Nil Nil Nil Nil Nil Nil Nil Nil Nil 
NAD – No abnormalities detected. 
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Table No. 4: Effect of LOCFL on body weight in rotenone-induced Parkinson’s disease 
 
 
 
 
 
 
 
 
 
Values are expressed as mean ± SEM (n=6).  
Values in parentheses are the percent increase (↑) or decrease (↓) from their corresponding initial readings.  
* denotes p < 0.05; ns denotes p > 0.05 when compared to initial readings; when compared to the initial readings (Student’s 
Paired‘t’-test);  
LOCFL – lemongrass oil of Cymbopogon flexuosus leaves.  
 
 
Group Name 
Body weight (g) 
Initial Final (% change) 
Vehicle Control 198.75 ± 7.58 211.00 ± 3.10 (↑5.8%)ns 
Negative Control 218.50 ± 0.64 173.50 ± 16.50(↓20.59%)* 
Positive Control 
(Levodopa group) 
200.66 ± 4.97 207.50 ± 5.85 (↑3.29%)ns 
Low Dose Test 
Group 
195.00 ± 7.79 200.00 ± 8.24(↑2.5%)ns 
High Dose Test 
Group 
183.00 ± 1.05 212.00 ± 5.07(↑13.67%)ns 
LOCFL Alone 
Group 
207.66 ± 4.84 236.33 ± 7.53 (↑12.13%)ns 
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Table No. 5: Effect of LOCFL on open field test in rotenone-induced Parkinson’s disease rats 
Groups 
Day 0 Day 7 Day 14 Day 21 
Line 
crosses 
Central square 
Stretch 
attend 
posture- 
Duration 
(sec) 
Line 
crosses 
Central square 
Stretch 
attend 
posture- 
Duration 
(sec) 
Line 
crosses 
Central square Stretch 
attend 
posture- 
Duration 
(sec) 
Line 
crosse
s 
Central square Stretch 
attend 
posture- 
Duration 
(sec) 
Number 
of 
entries 
Time 
spent 
(sec) 
Number 
of 
entries 
Time 
spent 
(sec) 
Number 
of 
entries 
Time 
spent 
(sec) 
Number 
of 
entries 
Time 
spent 
(sec) 
Vehicle 
Control 
95.00 ± 
9.46 
2.00 ± 
0.07 
5.50 
± 
0.50 
28.25 ± 
6.19 
129.25 
± 6.88 
16.02 ± 
0.04 
26.00 
± 2.00 
20.00 ± 
8.00 
130.25 
± 5.77 
16.25 
± 0.52 
35.00 
± 1.78 
40.00 ±  
2.00 
117.25 
± 
15.41 
15.78 ± 
1.52 
32.08 
± 1.86 
22.50 ± 
3.80 
Negative 
Control 
71.00 ± 
3.53 
3.00 ± 
1.95 
7.00 
± 
1.95 
36.20 ± 
5.85 
36.00 ± 
7.16
### 
1.80 ± 
0.80
## 
4.50 ± 
1.80
### 
228.83 
± 
24.62
### 
43.16 ± 
4.62### 
1.73 ± 
0.77### 
3.80 ± 
0.83### 
174.00 
± 
24.00## 
21.50 
± 
4.22### 
1.08 ± 
0.18## 
3.08 ± 
0.06### 
137.16 
± 
20.32## 
Positive 
Control 
(Levodopa 
group) 
92.60 ± 
3.05 
4.00 ± 
1.08 
9.50 
± 
2.84 
31.00 ± 
5.80 
104.40 
± 
11.33
*** 
14.60 ± 
1.07
** 
27.73 
± 
0.83
*** 
44.40 ± 
7.35
*** 
94.60 ± 
6.24*** 
15.45 
± 
0.83** 
21.08 
± 
0.08** 
40.66 ± 
4.48** 
93.60 
± 
6.34*** 
16.54 ± 
1.83** 
26.88 
± 
1.06** 
52.80 ± 
3.39** 
Low Dose 
Test 
Group 
86.25 ± 
4.73 
3.40 ± 
0.87 
11.80 
± 
3.05 
36.80 ± 
6.06 
115.60 
± 
7.91
*** 
18.00 ± 
1.58
*** 
19.91 
± 
0.09
** 
34.00 ± 
6.06
*** 
101.20 
± 
5.26*** 
17.77 
± 
0.73*** 
28.89 
± 
1.08*** 
47.66 ± 
12.38** 
103.00 
± 
6.33*** 
19.93 ± 
1.91** 
23.43 
± 
1.08*** 
60.33 ± 
12.44* 
High Dose 
Test 
Group 
91.80 ± 
3.63 
2.00 ± 
0.54 
4.80 
± 
0.96 
37.50 ± 
6.98 
144.33 
± 
7.32
*** 
21.60 ± 
1.07
*** 
33.03 
± 
0.08
*** 
47.33 ± 
12.19
*** 
131.16 
± 
11.12*** 
21.01 
± 
0.23*** 
43.08 
± 
1.48*** 
22.66 ± 
5.78** 
117.16 
± 
7.10*** 
23.12 ± 
0.98*** 
46.06 
± 
0.30*** 
58.75 ± 
8.14* 
LOCFL 
Alone 
Group 
86.50 ± 
7.85 
4.00 ± 
1.15 
10.66 
± 
3.71 
32.33 ± 
7.88 
122.66 
± 
7.96
ns 
18.00 ± 
0.50
ns 
28.13 
± 
0.33
ns 
34.00 ± 
19.00
ns 
125.00 
± 4.72ns 
18.15 
± 
1.26ns 
32.32 
± 
0.38ns 
31.75 ± 
4.09ns 
120.25 
± 
7.64ns 
18.78 ± 
1.34ns 
30.83 
± 
1.68ns 
20.50 ± 
2.50ns 
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Table No. 6: Effect of LOCFL on Rotarod test in rotenone-induced Parkinson’s disease rats  
 
Treatment 
Fall off time (sec) 
Day 0 Day 1 Day 7 Day 14 Day 21 
Vehicle Control 180 ± 0 180 ± 0 180 ± 0 180 ± 0 180 ± 0 
Negative Control 180 ± 0 25.50 ± 2.21### 18.16 ± 5.30### 19.16 ± 3.71### 15.20 ± 3.65### 
Positive Control 
(Levodopa 
group) 
180 ± 0 75.33 ± 3.93*** 90.00 ± 17.13** 109.80 ± 18.32*** 126.40 ± 14.15*** 
Low Dose Test 
Group 
180 ± 0 84.00 ± 4.05*** 136.00 ± 11.12*** 128.00 ± 9.75*** 133.00 ± 7.21*** 
High Dose Test 
Group 
180 ± 0 99.00 ± 2.22*** 128.33 ± 8.90*** 150.00 ± 7.41*** 144.33 ± 8.67*** 
LOCFL Alone 
Group 
180 ± 0 180 ± 0ns 180 ± 0ns 180 ± 0ns 180 ± 0ns 
 
Values are expressed in mean ± SEM (n=6).  
### denotes p < 0.001 when compared to vehicle control group; **denotes p < 0.01 when compared to negative 
control group; ***denotes p < 0.001 when compared to negative control group; ns denotes p > 0.05 when compared 
to vehicle control group (One way ANOVA followed by Tukey test).  
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Table No. 7: Effect of LOCFL on elevated plus maze test in rotenone-induced Parkinson’s disease rats  
Treatment 
Day 0 Day 7 
First preference Number of entries Time spent (sec) First preference Number of entries Time spent (sec) 
Open arm Closed arm Open arm Closed arm Open arm Closed arm Open arm Closed arm Open arm Closed arm Open arm Closed arm 
Vehicle Control + - 2.66 ± 0.49 1.75 ± 0.47 162.28 ± 1.03 143.62 ± 2.82 + - 14.30 ± 0.04 2.12 ± 0.57 232.75 ± 9.25 73.08 ± 1.26 
Negative Control - + 2.80 ± 0.58 2.20 ± 0.37 153.82 ± 0.28 144.78 ± 2.93 - + 3.01 ± 0.28
### 12.63 ± 
0.66## 
67.33 ± 
4.27### 
243.38 ± 
2.60## 
Positive Control 
(Levodopa group) 
+ - 2.00 ± 0.40 2.33 ±0.33 232.75 ± 2.95 78.62 ± 1.62 + - 
12.53 ± 
0.28*** 
1.83 ± 0.44*** 
246.60 ± 
3.75*** 
62.18 ± 
4.62*** 
Low Dose Test Group + - 1.75 ± 0.25 2.00 ± 0.36 198.03 ± 2.81 103.73 ± 2.13 + - 
10.53 ± 
0.05** 
2.32 ± 0.32** 
234.80 ± 
3.55*** 
71.73 ± 
3.48** 
High Dose Test 
Group 
+ - 2.50 ± 0.42 2.00 ± 0.36 173.33 ± 0.73 133.08 ± 1.37 + - 
11.10 ± 
0.18** 
2.78 ± 0.05** 
226.40 ± 
8.76** 
67.08 ± 
2.46*** 
LOCFL Alone Group + - 2.66 ± 0.49 2.00 ± 0.40 173.33 ± 1.82 132.73 ± 3.77 + - 
12.60 ± 
0.63ns 
2.43 ± 0.04ns 
234.66 ± 
5.60ns 
77.08 ± 
2.16ns 
 
Treatment 
Day 14 Day 21 
First preference Number of entries Time spent (sec) First preference Number of entries Time spent (sec) 
Open arm Closed arm Open arm Closed arm Open arm Closed arm Open arm Closed arm Open arm Closed arm Open arm Closed arm 
Vehicle Control + - 
12.16 ± 
1.02 
3.43 ± 0.04 253.08 ± 0.93 46.82 ± 1.83 + - 11.63 ± 1.20 3.04 ± 0.08 243.00 ± 2.22 56.83 ± 1.82 
Negative Control - + 
2.53 ± 
0.51## 
12.86 ± 
0.08## 
68.76 ± 
1.93### 
238.64 ± 
2.76### 
- + 2.04 ± 0.55## 
13.57 ± 
1.07## 
43.82 ± 
2.67### 
256.62 ± 
2.66### 
Positive Control 
(Levodopa group) 
+ - 
12.51 ± 
0.25** 
2.48 ± 0.03** 
248.43 ± 
1.36** 
62.02 ± 
2.02*** 
+ - 
12.36 ± 
1.08** 
4.32 ± 2.12** 
258.62 ± 
4.08*** 
46.83 ± 
2.42*** 
Low Dose Test Group + - 
11.43 ± 
0.34** 
3.82 ± 0.08** 
272.83 ± 
1.88*** 
34.44 ± 
1.93*** 
+ - 
11.62 ± 
1.26** 
3.46 ± 0.12** 268.08 ± 4.82 
43.38 ± 
1.84*** 
High Dose Test 
Group 
+ - 
14.84 ± 
0.08** 
2.08 ± 
0.06*** 
264.45 ± 
2.73*** 
46.48 ± 
2.62*** 
+ - 
13.32 ± 
2.80** 
2.06 ± 0.06*** 
256.82 ± 
3.83*** 
62.73 ± 
2.76** 
LOCFL Alone Group + - 
12.78 ± 
0.12ns 
4.34 ± 0.04ns 
258.32 ± 
2.86ns 
52.28 ± 
2.28ns 
+ - 
12.36 ± 
1.57ns 
3.14 ± 0.06ns 
267.28 ± 
1.08ns 
58.38 ± 
2.83ns 
Values are expressed in mean ± SEM (n=6). 
## denotes p < 0.01 and### denotes p < 0.001 when compared to vehicle control rats; ** denotes p < 0.01 and *** denotes  
p < 0.001 when compared to negative control rats. 
ns denotes p > 0.05 when compared to vehicle control group (One way ANOVA followed by Tukey test).  
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Table No.8: Effect of LOCFL on catatonia in rotenone-induced Parkinson’s disease rats  
Treatment 
Catatonic response  (Score) 
Day 0 Day 1 Day 7 Day 14 Day 21 
Vehicle Control 3.12 ± 0.12 3.00 ± 0.20 3.12 ± 0.12 3.12 ± 0.12 3.00 ± 0.35 
Negative Control 2.37 ± 0.12 1.25 ± 0.34### 1.50 ± 0.34### 1.08 ± 0.20### 1.16 ± 0.33## 
Positive Control 
(Levodopa 
group) 
2.80 ± 0.12 2.75 ± 0.21** 3.00 ± 0.15*** 3.00 ± 0.15*** 3.00 ± 0.20** 
Low Dose Test 
Group 
2.90 ± 0.10 2.58 ± 0.23** 3.10 ± 0.18*** 2.80 ± 0.25*** 3.20 ± 0.12*** 
High Dose Test 
Group 
2.90 ± 0.10 2.66 ± 0.16** 2.91 ± 0.08*** 3.08 ± 0.08*** 3.00 ± 0.25*** 
LOCFL Alone 
Group 
2.83 ± 0.16 3.00 ± 0.20ns 3.00 ± 0.20ns 3.16 ± 0.16ns 3.33 ± 0.16ns 
 
Values are expressed in mean ± SEM (n=6). 
 
### denotes p < 0.001 when compared to vehicle control rats; ** denotes p < 0.01 and *** denotes p < 0.001 when compared 
to negative control rats. 
ns denotes p > 0.05 when compared to vehicle control group (One way ANOVA followed by Tukey test).  
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Table No. 9: Effect of LOCFL on Rearing Behavior in rotenone-induced Parkinson’s disease rats  
 
Treatment 
Number of rears within 5 min 
Day 0 Day 1 Day 7 Day 14 Day 21 
Vehicle Control 14.75 ± 1.25 12.00 ± 0.81 10.25 ± 0.85 17.00 ± 0.70 16.25 ± 0.75 
Negative Control 9.80 ± 0.37 9.50 ± 0.28 2.00± 0.57### 1.66 ± 0.21### 1.75 ± 0.47### 
Positive Control 
(Levodopa group) 
14.00 ± 1.15 12.60 ± 1.50 12.40 ± 1.20*** 13.40 ± 0.92*** 14.20 ± 0.86*** 
Low Dose Test 
Group 
13.00 ± 0.70 10.80 ± 0.86 12.00 ± 1.09*** 10.20 ± 0.58*** 10.40 ± 0.50*** 
High Dose Test 
Group 
13.40 ± 1.24 11.20 ± 0.86 11.50 ± 0.76*** 15.50 ± 1.38*** 15.50 ± 0.88*** 
LOCFL Alone 
Group 
16.75 ± 0.75 14.75 ± 0.75 14.25 ± 1.75ns 12.33 ± 0.88ns 16.00 ± 1.00ns 
 
Values are expressed in mean ± SEM (n=6). 
 
### denotes p < 0.001 when compared to vehicle control rats; *** denotes p < 0.001 when compared to negative control 
rats.  
ns denotes p > 0.05 when compared to vehicle control group (One way ANOVA followed by Tukey test).  
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Table  No. 10: Effect of LOCFL on Postural instability test in rotenone-induced Parkinson’s disease rats 
 
Treatment 
Size of the adjusting response 
Day 0 Day 1 Day 7 Day 14 Day 21 
Vehicle Control 10.50 ± 0.64 10.00 ± 0.91 10.00 ± 1.08 10.75 ± 0.75 11.25 ± 0.75 
Negative Control 13.16 ± 1.60 4.00 ± 0.44### 4.50 ± 0.64## 4.75 ± 0.47### 5.00 ± 1.00## 
Positive Control 
(Levodopa group) 
11.50 ± 0.76 8.50 ± 0.50*** 11.40 ± 0.97*** 10.60 ± 0.60*** 9.80 ± 0.66* 
Low Dose Test Group 11.66 ± 0.76 10.00 ± 0.81*** 11.20 ± 0.96*** 10.60 ± 1.07*** 11.00 ± 0.70** 
High Dose Test Group 15.66 ± 0.55 9.60 ± 0.67*** 11.50 ± 0.76*** 11.66 ± 0.66*** 11.33 ± 0.91** 
LOCFL Alone Group 12.25 ± 1.10 10.25 ± 0.62ns 13.50 ± 0.64ns 12.00 ± 1.15ns 13.00 ± 1.15ns 
 
Values are expressed in mean ± SEM (n=6). 
 
## denotes p < 0.01 and ### denotes p < 0.001 when compared to vehicle control rats. 
** denotes p < 0.01 and *** denotes p < 0.001 when compared to negative control rats.  
ns denotes p > 0.05 when compared to vehicle control group (One way ANOVA followed by Tukey test).  
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Table No. 11: Effect of LOCFL on serum marker enzymes and LDH in rotenone-induced Parkinson’s disease rats. 
 
Treatment ALP (IU/L) AST (IU/L) ALT (IU/L) LDH (IU/L) 
Vehicle Control 307.39 ± 71.42 19.53 ± 18.33 30.32 ± 7.07 41.09 ± 9.20 
Negative Control 1625.11 ±122.65### 208.90 ± 35.38# 76.13 ± 8.47# 759.61 ± 83.18### 
Positive Control 
(Levodopa group) 
614.56 ± 214.43** 21.14 ± 31.09** 11.95 ± 5.39** 45.52 ± 12.82** 
Low Dose Test 
Group 
415.93 ± 132.68** 19.70 ± 4.02* 32.83 ± 5.45* 57.17 ± 9.77** 
High Dose Test 
Group 
407.35 ± 204.25** 1.17 ± 0.64* 7.43 ± 2.83*** 32.74 ± 3.18*** 
LOCFL Alone Group 789.31 ± 106.62ns 23.96 ± 9.63ns 34.48 ± 4.71ns 38.11 ± 6.45ns 
 
Values are expressed in mean ± SEM (n=6). 
 
# denotes p < 0.05 and ### denotes p < 0.001 when compared to vehicle control rats. 
** denotes p < 0.01 and *** denotes p < 0.001 when compared to negative control rats.  
ns denotes p > 0.05 when compared to vehicle control group (One way ANOVA followed by Tukey’s test).  
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Table No.12: Effect of LOCFL on protein and MDA in the brain tissues of rotenone-induced Parkinsonian rats 
 
Treatment Total protein (µg/mg wet tissue) MDA (nmoles/min/mg protein) 
Vehicle Control 1.35 ± 0.34 0.36 ± 0.08 
Negative Control 0.56 ± 0.16# 0.90 ± 0.06## 
Positive Control 
(Levodopa group) 
1.16 ± 0.19* 0.35 ± 0.05*** 
Low Dose Test 
Group 
1.20 ± 0.05* 0.45 ± 0.06** 
High Dose Test 
Group 
1.90 ± 0.24*** 0.47 ± 0.06*** 
LOCFL Alone 
Group 
1.25 ± 0.05ns 0.76 ± 0.05ns 
 
Values are expressed in mean ± SEM (n=6). 
 
# denotes p < 0.05 and ## denotes p < 0.01 when compared to vehicle control rats. 
* denotes p < 0.05; ** denotes p < 0.01 and *** denotes p < 0.001 when compared to negative control rats.  
ns denotes p > 0.05 when compared to vehicle control group (One way ANOVA followed by Tukey’s test). 
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Table No. 13: Effect of LOCFL on enzymatic and non-enzymatic antioxidants in the brain tissue of rotenone-
induced Parkinsonian rats 
 
Groups 
Enzymatic antioxidants 
Non enzymatic 
antioxidants 
SOD 
(nmoles/min/mg 
protein) 
CAT 
(µg/min/mg 
protein) 
GPx 
(nmoles/min/mg 
protein) 
GSSH 
(nmoles/min/
mg protein) 
GSH 
(nmoles/min/mg 
protein) 
Vehicle Control 15.85 ±2.31 29.86 ± 5.38 26.69 ± 3.30 15.58 ± 2.03 12.10 ± 0.50 
Negative Control 6.56 ± 0.76 13.69 ± 1.52## 8.49 ± 0.56## 4.92 ± 0.85# 4.83 ± 0.94## 
Positive Control 
(Levodopa group) 
16.96 ± 2.92 30.25 ± 2.64*** 21.63 ± 3.09* 15.09 ± 0.78* 12.94 ± 0.99** 
Low Dose Test 
Group 
15.03 ± 0.88 28.27 ± 1.70** 22.43 ± 2.91* 16.26 ± 1.29* 14.24 ± 1.31*** 
High Dose Test 
Group 
21.45 ± 2.04 33.14 ±2.25*** 42.60 ± 4.81*** 
23.16 ± 
3.91*** 
16.17 ± 1.80*** 
LOCFL Alone Group 15.09 ± 0.62 27.93 ± 0.65ns 30.16 ± 1.01ns 
14.65 ± 
1.67ns 
12.78 ± 0.28ns 
 
Values are expressed in mean ± SEM (n=6). 
 
# denotes p < 0.05 and ## denotes p < 0.01 when compared to vehicle control rats. 
* denotes p < 0.05; ** denotes p < 0.01 and *** denotes p < 0.001 when compared to negative control rats.  
ns denotes p > 0.05 when compared to vehicle control group (One way ANOVA followed by Tukey’s test). 
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Fig. No. 15: Histopathology of brain tissue isolated from normal and 
rotenone-induced Parkinsonian rats 
The Vehicle Control showed normal intact neurons with visible nuclei. The 
rotenone-induced Parkinsonian (Negative Control) rat brain tissue showed 
central vacuoles, decreased density of the cells, architecture completely altered 
featuring indisctint neuronal boundaries and invisible nuclei, also seen were 
haemorrhage and neuronal cell death. There is a significant reversal of the 
damage in levodopa-treated (Positive Control) and LOCFL-treated Parkinsonian 
rats.  
 
  
Vehicle Control Negative Control 
Positive Control LOCFL Treated 
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DISCUSSION AND CONCLUSION 
Parkinson’s disease (PD) is the second most common neurodegenerative 
disease, with an estimated prevalence of about 0.3%, affecting 1–2% of people 
over 60 years of age. The pathological hallmark of PD is loss of dopaminergic 
neurons in the substantia nigra, and the presence of protein aggregates such as 
Lewy bodies involving synuclein alpha (SNCA) in the residual dopaminergic 
neurons [67]. The cause of chronic nigral cell death in PD and the underlying 
mechanisms remain elusive. 
Plants, in the form of herbs, spices and foods, constitute an unlimited 
source of molecules available for improving human health. Cymbopogon 
flexuosus (lemon grass) belongs to a genus of plant species known for 
containing essential oil, which has a wide variety of chemical constituents used in 
perfumery, pharmaceutical industries and yield isolates which are used in high 
grade perfumery [23]. Essential oils and the phytoconstituents isolated from them 
are widely used to treat many human diseases [68]. Constituents of essential oils 
are widely known to have antioxidative property with several modes of actions as 
antioxidant, such as prevention of chain initiation, free radical scavengers, 
reducing agents, termination of peroxides, prevention of continued hydrogen 
abstraction as well as quenchers of singlet oxygen formation and binding of 
transition metal ion catalysts [69]. 
Animal models are only valuable as models for human diseases if they are 
actually reflect the diseased state in man, i.e., the model should simulate the 
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pathological, histological and biochemical changes of the disease and their 
resulting functional disturbances. Neurons are extremely dependent on 
mitochondria; they derive more than 90% of their ATP from mitochondrial 
respiration. The brain accounts for about 2% of body weight but receives about 
20% of the cardiac output and consumes about 20% of the body’s oxygen 
supply.  
Rotenone, a mitochondrial NADH dehydrogenase inhibitor and selective 
inhibitor of complex I, act by markedly delayed opening of the mitochondrial 
permeabilty transition pore and increased the calcium capacity of  
mitochondria [70, 71, 72]. It induces neuronal injury through multiple 
pathophysiological mechanisms viz. complex I inhibition, oxidative damage, 
microglial activation, production of ROS, apoptosis and synuclein aggregation[73]. 
The resulting mitochondrial dysfunction may cause α-synuclein aggregation or 
neurodegeneration through oxidative stress or excitotoxicity[74]. Respiratory chain 
defect in Parkinson's disease (PD) provides not only a direct link with toxin 
models of Parkinsonism but also insight into the mechanisms involved in etiology 
and pathogenesis. Rotenone exposure accurately recapitulated the pathological, 
biochemical, and behavioral features of PD [70]. 
The vast majority of studies on health benefits of phytochemicals have 
focused on the fact that many of the active chemicals possess antioxidant 
activity. Neuroprotective effects of various phytochemicals, which possess fatty 
acids, phenols, alkaloids, flavonoids, saponins, terpenes etc., as 
phytoconstituents, are associated with reduced levels of oxidative stress [75]. 
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Neuroprotective active phytochemical substances include. Lemon grass oil 
obtained from Cymbopogon flexuosus was found to possess most of the 
phytochemicals carbohydrates, proteins, amino acids, glycosides, saponins, 
flavonoids, etc. Hence it can be hypothesized that the plant/oil can be useful to 
be protective against neurotoxicity inflicted by rotenone.  
The acute toxicity study was carried out as per the OECD guidelines 
No.420 [52] and was found that the oil is coming under the category 5 (considered 
to be safe for the use in animals and humans); since it was not producing any 
toxic reactions even tested at the highest dose, i.e., 2000 mg/kg body weight. 
The LD50 was fixed at 2000 mg/kg and two dose levels were tested, i.e., 100 
mg/kg and 200 mg/kg. Two dose levels were used to ascertain any dose 
dependent increase in the protection shown by the oil. 
The experimental design consisted of the use of rats under vehicle control 
(coconut oil alone); negative control (rotenone alone); positive control (rotenone 
and levodopa); two test groups (rotenone and two dose levels of lemon grass oil 
extracted from Cymbopogon flexuosus) and oil alone (lemon grass oil alone). 
The oil alone group was tested to learn any difference caused by treatment of oil 
alone without any neurotoxic substance.  
Post treatment there was slight non-significant (P>0.05) increase in the 
body weight of the rats except for the rotenone-alone group, which had showed a 
significant (p<0.05) decrease. This may be attributed to the development of 
Parkinsonism in those rats. Possible determinants of weight loss in PD patients 
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may be due to hyposmia, impaired hand–mouth coordination, difficulty chewing, 
dysphagia, intestinal hypomotility, depression, decreased reward processing of 
dopaminergic mesolimbic regions, nausea, and anorexia as the side effects of 
medication, and increased energy requirements due to muscular rigidity and 
involuntary movements [76]. 
Behavioural alterations and loss of dopaminergic neurons in the 
substantia nigra pars compacta (SNc) are seen in toxin-induced Parkinsonism 
diseased rats as seen in idiopathic Parkinsonism patients. The same has been 
documented by many authors [72], [77], [78], [79], [80]. A variety of tests have been 
proposed for evaluation of motor deficits in rat models of Parkinsonism. They 
include, open field test, Rotarod, elevated plus maze, catalepsy, rearing 
behaviour, etc.  
Open field and elevated plus maze tests are important test to evaluate the 
changes in locomotion, exploration and anxiety in animals. Changes in 
locomotion and anxiety are critical parameters in Parkinsonism patients. Anxiety 
disorders are usually under diagnosed and under treated in these patients [81]. 
Thus ability of lemon grass oil to reverse the rotenone-induced changes in 
locomotion and anxiety in rats can be evidenced.  
Another widely used test is the “rotational behaviour” test usually using a 
Rotarod apparatus. It is based upon motor asymmetry induced by rotenone 
administration, leading to problems of sensitization, conditioning and priming [78]. 
Rotational behaviour is reproducible and easy to quantify. 
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Catalepsy is a state characterised by a patient keeping an uncomfortable, 
rigid and fixed posture despite external stimulus or resistance. There may also be 
decreased sensitivity to pain. It is a feature seen in catatonia. Catatonia is a 
major dysregulation syndrome that occurs in various medical conditions including 
Parkinsonism [82]. Drug-induced catalepsy can be used as a measure to evaluate 
effects on catatonia in Parkinsonism diseased rats.  
The rearing behaviour or the cylinder test is one of the sensitive and 
reliable tests in detecting loss neuronal activity in the substantia nigra [80]. 
Postural instability is one of the many behavioral deficits observed in common 
animal models of PD. In the Parkinsonism diseased rat, there is a decreased 
reliance on the impaired forelimb for movements involving a response to weight 
shift. The animals preferentially initiate movement with the non-impaired forelimb, 
particularly for lateral movements during vertical exploration of surfaces [83].   
In the present study, rotenone-induced Parkinson diseased rats showed 
significant changes in behavioural parameters which was reversed by presence 
of levodopa or lemon grass oil. Two doses of lemon grass oil also showed 
proportional increase in reversal of change in parameters.  
An increase in serum parameters like serum glutamic-oxalacetic 
transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT) and 
alkaline phosphatase (ALP) is seen in Parkinsonism diseased rats [84]. Elevation 
in serum lactate dehydrogenase (LDH) is seen in Parkinson’s disorder [85]. 
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Rotenone-induced Parkinsonism rats showed similar response and the same 
was reversed by treatment with levodopa and lemon grass oil.  
Among the long list of neurological diseases linked to oxidative stress, not 
only will one find all sorts of acute disorders, but also, almost invariably, all of the 
prominent neurodegenerative disorders including Parkinson's disease (PD) [86]. 
Some of the oxidant-mediated alterations in cellular components are stable 
modifications and can thus be readily detected and quantified. The levels of 
enzymatic and non-enzymatic antioxidants in the brain tissue would be a good 
measure of oxidative status of the animal brain. In rotenone alone administered 
animals the oxidative stress was evident in the increase in levels of 
malondialdehyde, a thiobarbituric acid reactive substance, and a good indicator 
of oxidative stress. The levels of superoxide dismutase, catalase, glutathione 
peroxidase, glutathione reductase, reduced glutathione are severely reduced in 
rotenone treated animals since the antioxidants are used up in the process of 
scavenging the free radicals. The levels are increased in levodopa and lemon 
grass oil treated animals.  
The results of histopathological analysis also confirmed the extent of 
damage caused by rotenone in the brain and resultant reversal of the damage 
upon treatment with lemon grass oil. The findings correlate with results in the 
behavioural, serum and tissue parameters.  
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Conclusion: 
Many phytochemicals have been reported to exert neuroprotective effects 
in various experimental models of neurological disorders. Although demand for 
phytotherapeutic agents is growing, there is need for their scientific validation 
before plant–derived substances gain wider acceptance and use. These type of 
investigations may provide a new source of beneficial neuropsychotropic drugs. 
They may also provide a phytochemical basis for some of the effects that these 
herbal preparations have on brain function and neuroprotection. Most of the 
current knowledge about CNS-active plants of cultural and traditional importance 
arose from ethnobotanical and ethnopharmaceutical uses, as for other natural 
active ingredients. Moreover, for a suitable neuroprotective agent, a very 
important property regards its ability to cross the blood-brain barrier (BBB), in 
order to reach the neurons in the nigrostriatum.  
Finally, though the presence of receptors or transporters for 
phytochemicals in brain tissues remains to be ascertained and compounds with 
multiple targets appear as a potential and promising class of therapeutics for the 
treatment of Parkinsonism. 
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